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CARDIOPROTECTIVE ROLES OF HYDROGEN SULFIDE DONOR TREATMENT
IN DIABETIC CARDIOMYOPATHY
Sumit Kar, Ph.D.
University of Nebraska, 2020
Supervisor: Paras K. Mishra, Ph.D.
Diabetes mellitus (DM) increases the risk of heart failure 2-4-fold. Intensive glycemic control does not abate this risk in DM patients, suggesting that DM-induced heart
failure is beyond hyperglycemia. DM silently induces cardiac muscle disorder termed diabetic cardiomyopathy (DMCM), which progresses to heart failure. The objective of this
dissertation is to understand the mechanistic underpinnings of DMCM to develop new
solutions to diagnose and treat heart failure in DM.
The heart pumps blood due to contraction and relaxation of terminally differentiated cardiomyocytes with limited regenerative capacity. The DM environment of hyperglycemia, hyperlipidemia, and inflammation causes cardiomyocyte death and leads to
hypertrophy, fibrosis, and heart failure progression. Apoptosis, the most studied form of
cell death, contributes minimally (0.025%) to cardiomyocyte death in the failing heart.
Thus, non-apoptotic forms of cell death predominate, but their molecular mechanisms
are unclear in the DM heart.
Pyroptosis is an inflammatory non-apoptotic cell death pathway shown to occur
in cardiomyopathies. Ferroptosis is a newly discovered form of cell death, which is triggered by the accumulation of intracellular iron, lipids, and oxidative stress. Although inflammation, lipotoxicity, iron overload, and oxidative stress are hallmarks of DMCM, the
role of cardiac pyroptosis and ferroptosis in DMCM remains unclear.
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Hydrogen sulfide (H₂S) is a gaseous signaling molecule that has been shown to
inhibit multiple forms of cell death. Systemic and cardiac levels of H₂S are reduced in
DM. We hypothesized that DM induces non-apoptotic cell death which may be prevented by elevating endogenous H₂S. We also investigated if exercise training has cardioprotective effects in DMCM via H₂S upregulation.
Our results demonstrated that reduced expression of H₂S biosynthesis enzymes
increased pyroptosis and caused cardiac remodeling. DM hearts also demonstrated increased pyroptosis and ferroptosis. H₂S donor treatment or exercise training increased
cardiac H₂S levels, inhibited pyroptosis and ferroptosis signaling, and prevented adverse
cardiac remodeling and dysfunction.
Our studies demonstrate how myocardial cell death contributes to DMCM progression. We conclude that targeting cell death, specifically by H₂S donor treatment
and/or exercise, could be a novel approach to mitigate DMCM and heart failure.
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INTRODUCTION
DIABETES MELLITUS & END ORGAN DAMAGE
According to the CDC (Centers for Disease Control and Prevention) Diabetes
mellitus (DM) currently affects more than 30 million US citizens and is projected to increase in prevalence as well as medical costs annually.(10) An additional 20% are at risk
of developing DM within the next five years.(137) DM is characterized by either lack of
insulin production from pancreatic beta cell death (T1DM) or decreased insulin sensitivity
(T2DM). Both types of DM can cause damage to organs such as the brain, liver, kidney,
and blood vessels.(117) However, cardiovascular complications such as hypertension,
coronary artery disease, and the development of heart failure are is the leading cause of
death in DM patients.(72)
DIABETIC CARDIOMYOPATHY
Diabetic cardiomyopathy (DMCM) is a primary diabetes mellitus (DM)-induced cardiac muscle disorder that can progress to heart failure (170). DMCM was first described
in autopsies of diabetic patients who died of heart failure without other cardiovascular
complications of DM (hypertension, coronary atherosclerosis).(145) It affects about 20%
of otherwise healthy DM patients. While it is believed that hyperglycemia leads to cardiac
remodeling and ultimately heart failure,(3) intensive glycemic control, the primary treatment for diabetes, does not reduce the risk of heart failure.(14, 22) Some DM medications
are also contraindicated.(125) Due to a lack of molecular biomarkers, DMCM is also difficult to diagnose before irreversible systolic dysfunction occurs.(130) These complications
have led to a mortality rate of 30% for DMCM.(30) The pathophysiology of DMCM are
complex, and new approaches are needed to understand, diagnose, and target the mechanisms causing DMCM.
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CELL DEATH IN DIABETIC CARDIOMYOPATHY
One of the critical components in the pathogenesis of DMCM is myocardial cell
death, which occurs in both T1 and T2DM hearts. The diabetic environment of hormones,
cytokines, hyperglycemia, hyperlipidemia, and adrenergic tone leads to death of terminally
differentiated cardiomyocytes, loss of contractile units, compensatory hypertrophy and fibrosis, and a progression to heart failure.(17) It is well demonstrated that major cell death
pathways like apoptosis, dysregulated autophagy, necrosis, ferroptosis and pyroptosis, all
play a role in the development and progression of DMCM and other cardiovascular diseases.(13) Targeting cell death has proven useful to prevent DMCM in rodents, and better
understanding the cell death signaling pathways that lead to pathological cardiac remodeling will uncover new therapeutic targets.(93, 108)
TYPES OF CARDIAC CELL DEATH
Currently, 12 distinct forms of cell death have been identified.(43) Six forms of
myocardial cell death have been observed: apoptosis, necroptosis, mitochondrial-mediated necrosis, pyroptosis, ferroptosis, and autophagic cell death.(120) While apoptosis
and necrosis are well established in the DM heart,(18) there is a lack of understanding of
other forms of cell death. Apoptosis, the most studied form of cell death, affects only about
250 per 105 cells (0.025%) in the failing human heart.(93, 185) This means non-apoptotic
cell death mechanisms predominate and must be better understood to prevent DMCM
progression. Non-apoptotic forms of cell death must be studied and targeted since inhibition of one cell death pathway can lead to compensation by other forms of cell death.(18)
H₂S MAY PREVENT DMCM & MYOCARDIAL CELL DEATH
The accumulation of reactive oxygen species (ROS) and reactive nitrogen species
have been shown to play a critical signaling role in the myocardial cell death process (178).

3
More recently, studies have revealed a growing role of reactive sulfide species in cell death
(87). Hydrogen sulfide (H₂S) is an endogenous, antioxidant, gaseous signaling molecule
that interacts with proteins present in body tissue and circulation (131). Plasma H₂S levels
are decreased in T2DM patients and high-fat diet–treated mice (8, 67, 69). In addition,
preclinical studies have shown that exogenous H₂S treatment ameliorates DMCM, suggesting that restoring H₂S levels may be a potential novel treatment option for DMCM (8).
There is also evidence suggesting non-pharmacological treatments such as exercise training (EX) may provide cardioprotection in DMCM. Notably, EX restores
bioavailability of H₂S in hepatocytes of HFD-fed mice (180). EX reduces cardiac mortality
in diabetic patients and increases cardiac output and contractility.(98, 188) EX was found
to normalize diastolic function in HFD-fed obese and T2DM mice.(36, 105) While other
gaseous signaling molecules such as nitric oxide (NO) have well established therapeutic
roles, comparatively little is known about signaling by H₂S, which has the potential to act
as a therapeutic gaseous molecule as well. Exogenous donors or non-pharmacological
treatments to restore H₂S have the potential to prevent DMCM.
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H₂S PRODUCTION AND SIGNALING
H₂S production is highly regulated,
and it is produced on demand due to its
potential toxicity at higher levels. All three
enzymatic pathways that produce H₂S are
centered on homocysteine (Hcy) and cysteine metabolism. As shown in Figure 0.1,
These pathways are cystathionine β-synthase (CBS), cystathionine gamma-lyase
(CSE), and the coupling of cysteine aminotransferase (CAT) and 3-mercapto- pyruvate sulfurtransferase (3-MST) (58, 87,
203). The expression of H₂S generating

Figure 0.1: Endogenous H2S biosynthesis is produced during the metabolism of homocysteine. Patients with diabetes have been shown to have reduced
H2S and increased homocysteine (red arrows).

enzymes are sub-cellular and tissue-specific. On a cellular level, CSE occurs strictly in the
cytoplasm, while CAT is located in the mitochondria. On tissue-specificity, CSE is most
abundant in the cardiovascular system (83), while CBS is predominant in the nervous
system and liver, and expressed in the heart. A growing body of research is uncovering a
role of H₂S in cellular signaling, similar to the other gasotransmitters. One of the
mechanisms by which H₂S signals cellular processes is by the sulfhydration of cysteine
residues of target proteins (131). This posttranslational modification is reversible by the
thioredoxin system, further lending credence to its role in signaling (11, 89).
H₂S signaling has been implicated in several cell death signaling processes within
the heart, and thus it may help prevent cell death in cardiomyopathy.
Pig and rat models of ischemia-reperfusion injury showed H₂S treatment reduced
apoptosis (129). A study by Shi et al. demonstrated reduced apoptosis in cells treated with
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H₂S during I/R and was mediated by inhibiting JNK kinase which is required for cytochrome c release into the cytosol (157).
Oxidative and nitrosative mechanisms have been shown to regulate autophagy in
cardiomyopathies, and recent evidence shows the importance of H₂S signaling in this process (178). A H₂S donor has been shown to protect against cell death in high glucosetreated cardiomyocytes via activation of AMPK, an essential autophagy regulator.
However, this study did not test whether the autophagic flux was also altered.
A limited number of studies have shown a role for H₂S signaling in pyroptosis in
other organs and in pathological conditions. Toldo et al. demonstrated that an H₂S donor
suppressed several pyroptosis activity markers (caspase-1 activity, caspase-1 recruitment
via the ASC adapter protein) in an I/R cardiomyopathy model (171). The role of pyroptosis
in DMCM and the mechanistic role of sulfide signaling in pyroptosis requires further studies.
H₂S also regulates key components of ferroptosis. In neurons, the addition of H₂S
increases levels of glutathione (GSH), an antioxidant,by directly stimulating GSH production and also increasing intracellular cysteine transport into the cell via the cysteine/glutamate antiporter (system Xc- or xCT).(56, 83) Increased GSH via H₂S should increase
GPX4 activity to inhibit lipid peroxidation. These studies suggest H₂S inhibits ferroptosis
in pathological conditions such as DMCM. The studies in this dissertation investigated
how H₂S regulates pyroptosis, autophagy, and ferroptosis in the DM heart to prevent
pathological cardiac remodeling.
GAP IN KNOWLEDGE
While many studies have characterized apoptosis and necrosis in DM human
and animal hearts, the role of non-apoptotic forms of cell death is not well understood.
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H₂S may prevent DMCM based on in vitro studies and limited in vivo testing. However,
more in vivo studies in multiple models of DMCM and multiple pharmacologic H₂S donors and non-pharmacologic interventions are needed to test this theory. Lastly, further
studies are needed to determine how H₂S prevents cell death in the DM heart. Answering these questions could translate into new therapeutics and biomarkers for DMCM,
which is currently difficult to diagnose and treat.
CENTRAL HYPOTHESIS AND RESEARCH GOALS
As highlighted earlier, deficiency of hydrogen sulfide (H₂S), a cardioprotective gas,
contributes to DMCM.(199) While there is one in vivo report showing H₂S donor treatment
prevented DMCM in a rat DMCM model,(97) and in vitro reports showing H₂S prevents
cell death in hyperglycemia treated cardiomyocytes,(74, 205) more in vivo studies are
needed to determine how H₂S prevents DMCM by inhibition of cell death. Therefore, my
central hypothesis is that DM induces increased non-apoptotic cell death signaling contributing to cell death, pathological cardiac remodeling, and ultimately DMCM (Figure 0.2).

Diabetic Heart
Hyperglycemia, oxidative
stress, hyperhomocysteinemia
(chapters 1-2), lipotoxicity

H2S donor treatment
(Chapter 3) or
Exercise Training (Chapter 4)
in Diabetic Heart

↑ H 2S

Activation of Non-Apoptotic Cell
Death Pathways
(e.g. pyroptosis, ferroptosis
(Chapters 2-4)

↓ Cell Death

Cell Death &
Diabetic
Cardiomyopathy

Ameliorated Cell
Death & Diabetic
Cardiomyopathy

Figure 0.2: Central hypothesis of the studies in this dissertation is assessing the role of non-apoptotic cell death in the pathogenesis of
DMCM and the ability of H2S and EX to ameliorate DMCM.
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We believe elevating endogenous H₂S by H₂S donor treatment will prevent this cell death
and ameliorate DMCM.
To address this hypothesis, my studies answer the following questions:
1) Research Goal 1 (Hydrogen sulfide ameliorates cardiac remodeling How does aberrant H₂S signaling lead to pathological cardiac remodeling and cardiomyopathy?
a) Does H₂S donor supplementation prevent cardiac remodeling in vivo?
2) Research Goal 2 (Hydrogen Sulfide Transcriptionally Regulates Cardiac Autophagy and PyroptosisIs prevention of remodeling/cardiomyopathy by H₂S due to cell
death signaling prevention?
3) Research Goal 3 (Hydrogen Sulfide Protects Against Cardiac Ferroptosis In Diabetic CardiomyopathyDoes H₂S supplementation prevent cardiac remodeling in vivo
in DMCM?
a) Is this also due to the prevention of non-apoptotic cell death signaling?
4) Research Goal 4 (Because of these signaling effects of H₂S upstream of the production of ROS, H₂S may act as a better therapeutic agent in DMCM. Vitamin E,
which should increase GSH and reduce ferroptosis, failed to reduce cardiovascular
disease in diabetic patients.(50, 103) This study and others suggest H₂S is a signaling molecule with effects besides being a direct antioxidant including regulating transcription factors and sulfhydrating proteins(2, 150) – which could be more efficacious
in halting DMCM.
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5) Exercise Training Promotes Cardiac Hydrogen Sulfide Biosynthesis and Mitigates Pyroptosis in Diabetic CardiomyopathyCan non-pharmacologic interventions such as EX
increase H₂S and ameliorate DMCM?
EXPERIMENTAL MODEL SYSTEMS
The experiments in this dissertation used both in vivo and in vitro models to study
the effects of H₂S on cardiomyocytes cell death and cardiac remodeling in DMCM:
CBS+/- mouse model of Hyperhomocysteinemia (HHcy): We first tested the hypothesis that H₂S donor supplementation prevents cardiac remodeling in a model with
aberrant H₂S biosynthesis. Deficiency of the H₂S producing enzyme cystathionine beta
synthase (CBS) elevates the levels of homocysteine (Hcy), which is termed HHcythat decreases H₂S levels. Mild HHcy is an independent risk factor for cardiovascular disease
development (59, 158, 159). In addition, patients with diabetes can develop HHcy, and
diabetic patients with HHcy are more likely to develop diabetic cardiomyopathy (DMCM)
(160, 175).
Our laboratory has shown HHcy is associated with the development of DMCM in
diabetic mouse models, and high glucose- treated cardiomyocytes (121), however, few
studies have investigated the molecular changes that HHcy and aberrant H₂S signaling
induces to cause cardiac remodeling. Use of this model allowed direct investigation of the
role of H₂S biosynthesis and signaling in cardiac remodeling and was translatable to determining the effect of H₂S donor supplementation in DMCM because of the comorbidity
between HHcy and DMCM.
Diabetes spontaneous mutation (Leprdb, db/db) mouse model of DMCM:
Based on our encouraging data from H₂S donor therapy in CBS+/- mice, we aimed to translate our findings to DMCM. The hypothesis that hydrogen sulfide donor treatment prevents
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DMCM and cardiac cell death was tested in vivo with the db/db model of DMCM. While
there are many animal models for DMCM, no model perfectly mimics the human condition.(5) I have chosen a Type II DM model instead of Type I DM due to its higher prevalence. This study will use db/db mice on the C57BL/6J background which reproducibly
develop severe hyperlipidemia, hyperinsulinemia, hyperglycemia (at 4-8 weeks of age, as
shown in Figure 4), diastolic dysfunction (reduced diastolic function seen by increased
end-diastolic volume (EDV) at 10 weeks), and systolic dysfunction (reduced fractional
shortening (%FS) at 12-14 weeks).(16, 148) db/db mice on the C57BLKS background was
not chosen since they develop rapid late-stage DM less likely to mimic human disease.
High Fat Diet (HFD)-Induced mouse model of DMCM: Obesity, primarily due to
changes in diet to higher fat and higher sugar foods, can lead to metabolic syndrome and
Type II DM (T2DM). Patients with diet-induced DM can develop diastolic dysfunction and
diabetic cardiomyopathy (DMCM).(1, 41, 179). To further translate our studies in genetic
DMCM models, we tested our hypothesis in mice with HFD-induced DMCM. HFD-induced
models of DMCM may induce alterations in lipid synthesis, inflammation, and metabolism
likely to induce cell death, and more closely mimic the human condition.
Primary Neonatal Mouse Cardiomyocytes: Cardiomyocytes are the primary cell
type in the heart, and cardiomyocytes' loss initiates cardiac remodeling. To determine how
the diabetic hyperglycemic environment activates cell death signaling and whether H₂S
can directly prevent cell death in cardiomyocytes, weconducted studies in cultured primary
cardiomyocytes. Primary isolated mouse cardiomyocytes were preferred since stable cancer-derived cardiomyocytes may have altered cell survival traits. Though best mimicking
the in vivo studies of this dissertation, adult mouse cardiomyocytes are challenging to
isolate and treat in hyperglycemic conditions. Therefore, I characterized cell death and the
effects of H₂S supplementation in cardiomyocytes isolated from neonatal mouse pups.
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EXPERIMENTAL HYDROGEN SULFIDE DONORS
Exogenous compounds can be administered to in vitro and in vivo model systems
to deliver active H₂S and increase endogenous H₂S. Sodium hydrogen sulfide (NaHS)
and sodium sulfide (Na2S) are two common water-soluble H₂S donors. However, they are
volatile and give a bolus of H₂S instead of a slow, steady release more likely to lead to
beneficial cardiac signaling and remodeling effects. (134) Therefore, this dissertation used
two slow-releasing donors of H₂S:
Dietary SG1002 (Figure 0.3) is a
novel long-acting synthetic prodrug of H₂S.
It has been tested in preclinical models of
cardiovascular disease and in clinical trials
(No.

NCT01989208

and

No.

NCT02278276) (7, 133). In an animal

Figure 0.3: Structure of the dietary
H2S donor SG1002.

model of systolic heart failure, SG1002
protects against adverse remodeling and heart failure via the upregulation of endothelial
nitric oxide synthase (133). It also prevented QT interval prolongation in mice with ischemic cardiomyopathy, suggesting a decrease in cell death (7). In phase I clinical trials,
SG1002 reduced BNP and increased NO in heart failure patients (132, 133). SG1002 is
also easily translatable to therapy as it is orally administered.
Intraperitoneal GYY4137 is a
water-soluble H₂S donor that slowly releases H₂S via hydrolysis (Figure 0.4).
GYY4137 is delivered by intravenous or
intraperitoneal injection releasing H₂S

Figure 0.4: The slow releasing H2S donor GYY4137 produces H2S endogenously by a hydrolysis reaction with
water.

11
with a peaking time of 10 minutes compared to 10 seconds for NaHS.
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CHAPTER 1: HYDROGEN SULFIDE AMELIORATES CARDIAC REMODELING
FROM ABERRANT H₂S BIOSYNTHESIS
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INTRODUCTION – I
The gaseous signaling molecule H₂S is produced endogenously during the metabolism of homocysteine (Hcy). To determine the role of H₂S in cardiac remodeling and
function, we treated mice which have a genetic defect in an enzyme that breaks down
Hcy and produces H₂S with an H₂S donor.
Elevated Hcy in plasma and tissue (hyperhomocysteinemia, HHcy) increases the
risk of developing cardiovascular disease (CVD). Mild HHcy (plasma homocysteine concentrations 15-30 μM) develops due to genetic deficiencies or polymorphisms in cystathionine-β-synthase (CBS) and methylenetetrahydrofolate reductase (MTHFR), folate and
vitamin B12 deficiency, and a methionine-rich meat diet (151, 176). Mild HHcy is an independent risk factor for the development of cardiovascular disease and other pathologies,
including diabetes, hypertension, and congenital abnormalities (59, 158, 159). Patients
with diabetes also show HHcy, possibly due to impaired kidney function and the effects of
glucose and insulin on decreased CBS activity and homocysteine tissue uptake (33, 42,
45, 124, 187). Also, HHcy works
synergistically as a comorbidity
with the detrimental effects of diabetes. Diabetic patients with HHcy
are more likely to develop diabetic
cardiomyopathy (DMCM) and are
more than 10% more likely to die
from CVD than diabetic patients
without HHcy as shown in Figure
1.1 (160, 175). HHcy has also

Figure 1.1: Patients with diabetes show elevated homocysteine. HHcy is strongly associated with the development of and death from cardiovascular disease including diabetic cardiomyopathy (Reproduced with permission from Soinio
et al. Ann Intern Med. 2004) (160).
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been associated with the development of DMCM in diabetic mouse models, and high glucose-treated cardiomyocytes (121). However, while the detrimental effects of HHcy on
CVD are well established, few studies have investigated the molecular changes that HHcy
induces on the heart.
Several placebo-controlled clinical trials have attempted to supplement folate,
which metabolizes homocysteine to methionine, in an attempt to reduce the detrimental
effects of HHcy on CVD (118, 163). Although all of these trials were able to reduce Hcy
concentrations in serum, a meta-analysis showed no change in the relative risk of developing CVD (9). Also, folate treatment in diabetic mice with HHcy did not alleviate the development of DMCM (121). These negative findings suggest that the detrimental effects
of HHcy are due to downstream products of Hcy metabolism and not Hcy itself.
Homocysteine is metabolized to cysteine by cystathionine-beta synthase (CBS),
and cystathionine ɣ-lyase (CSE) termed transsulfuration (152). Subsequently, the metabolism of cysteine by CBS and CSE produces hydrogen sulfide (H₂S). H₂S is an endogenous antioxidant gaseous signaling molecule and has been shown to have significant beneficial cardiovascular effects, unlike homocysteine (2, 133). H₂S reduces hypertension
(151, 166) and has a cardioprotective effect in cardiomyopathy models (100, 205).
Our lab has previously shown that HHcy mediates pathological cardiac remodeling
which is mediated in part by alterations in microRNA and altered beta-adrenergic signaling
(121, 123). In cultured cardiomyocytes, the administration of H₂S to HHcy subjected cardiomyocytes mitigated the molecular and histological signs of hypertrophy and remodeling
(80). However, the effects of H₂S in vivo during HHcy are unclear.

15
Hypothesis and Aims
We aimed to determine the molecular
and histological changes in the heart induced
by mild HHcy using CBS+/- mice which have
been previously shown to have circulating levels of homocysteine approximately two times
normal levels (4, 57). We further tested
whether H₂S supplementation in CBS+/- mice
can mitigate cardiac remodeling in vivo (Figure 1.2).

Figure 1.2: Research Goal I Hypothesis. We hypothesized CBS+/with reduction in the H2S biosynthesis
enzyme CBS and elevation of Hcy
show cardiac remodeling which can
be inhibited by H2S donor treatment.

METHODS – I
Experimental Models and H₂S Donor Diet
We procured CBS+/− mice from The Jackson Laboratory and bred these mice in
the University of Nebraska Medical Center's animal facility to obtain CBS+/+ (WT) mice. All
animal studies were performed following the National Institutes of Health guidelines and
protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of Nebraska Medical Center. The experimental plan for the mice is shown in
Figure 1.3.
SG1002 is a proprietary slow release and orally active H₂S donor (Sulfagenix, Inc).
We started 12-week-old male CBS+/- mice and their WT littermates on a SG1002 or control
diet (307 mg of SG1002/ kg of feed; Research Diets, Inc.; New Brunswick, NJ). The
SG1002 diet achieved a dose 40 mg/kg/d and was chosen based on previous clinical and
preclinical studies of SG1002 which demonstrated stable increases in H₂S from this dose
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(78, 133). Both diets contained a standard 15 kcal %fat. All groups were supplied with
food and water ad libitum. Mice were selected randomly for the different treatment groups.
For genotyping, genomic DNA was extracted from ear punch tissue and was amplified using the protocol provided by the Jackson Laboratory. The forward primer for
CBS+/+ and CBS+/− was 5′GATTGCTTGCCTCCCTACTG3′. The reverse primer sequence
for CBS+/+ was 5′AGCCAACTTAGCCCTTACCC3′, and for CBS+/− was 5′CGTGCAATCCATCTTGTTCA3′, respectively. cDNA was amplified in a BioRad cycler, and the
PCR product was separated on a 2% agarose gel. WT mice had one band at 308 bp
whereas CBS+/− were characterized by two bands at 308 bp and 450 bp (Figure 1.3B).
Evaluating Cardiac Function with Pressure-Volume Recording
We measured hemodynamic changes in the heart by pressure-volume (PV) loop
study following the best practice guidelines for invasive hemodynamic measurement in
mice described by Lindsey et al. (101). Mice were first anesthetized with 1-2% isoflurane,
intubated and connected to a ventilator (MidiVent, Harvard Apparatus, Cambridge, MA).
After opening the chest, a hole was made in the apex area of the left ventricle (LV) using
a 27-gauze needle to insert a 1.2F catheter probe (Transonic, Ithaca, NY). The probe was
advanced slowly into the LV so that it was away from the ventricle and septal walls as
observed by the phase measurements of the surrounding muscle derived from the catheter. We maintained body temperature at 37ᵒC by a temperature controller (ATC2000,
World Precision Instruments, Sarasota, FL). Because heart rate can affect hemodynamics,
we kept the heart rate between 450 and 500 beats per minute during PV recording by
adjusting anesthesia. Volume measurements were calibrated automatically by the probe
using admittance by removing parallel conductance from overall conductance and converted to an actual volume using the Weis equation accounting for body weight [33]. The
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calculated stroke volume was verified in one WT animal by echocardiography. Hemodynamic parameters of diastolic and systolic function were determined by averaging at least
20 cardiac cycles from a baseline portion of the recording after proper probe placement
was confirmed using the LabChart Pro PV Loop Analysis Add-On.
After recording was completed, mice were euthanized and organs were harvested
cryopreserved at -80ᵒC for later analyses. Approximately 200 ul of blood was collected
from the inferior vena cava and centrifuged 20 min at 3000xG, and the resulting serum
was stored at -80ᵒC in a microcentrifuge tube.
H₂S Measurement
H₂S levels were measured in serum using gas chromatography, as previously described (136). 0.2 ml blood, previously frozen at -80ᵒ C was incubated with 1 M sodium
citrate buffer (pH 6.0), sealed, at 37°C for 10 min with shaking at 125 rpm to release of
H₂S gas. Then, 0.1 ml the headspace gas was injected into a gas chromatograph (7890A
GC System, Agilent, Santa Clara, CA) equipped with a dual plasma controller and chemiluminescence sulfur detector (355, Agilent) for H₂S quantification against a standard
curve. The samples were blinded for this measurement.
Cysteine and Homocysteine Measurement
Cysteine concentrations in serum were measured by a fluorometric enzymatic assay (211099, Abcam) following the manufacturer’s protocol. A standard curve with five
standards from 0 nM to 10 nM of cysteine was prepared in the manufacturer’s assay buffer.
10 µl of neat serum was added to each well and incubated with enzyme mix and detection
reagent. Homocysteine concentrations in serum were similarly measured by a fluorometric
enzymatic assay (228559, Abcam). 10 µl of neat serum was added to each well and incubated with enzyme mix and detection reagent. Each serum sample for the homocysteine
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assay was also run without enzyme mix in separate wells to measure background fluorescence.
The assay plate was read using a fluorescence plate reader (Glomax Multi+,
Promega, Madison, WI) at an excitation wavelength of 365 nm and emission at 450 nm
(cysteine assay) or at an excitation wavelength of 625 nm and emission at 708 nm (homocysteine assay). Readings were taken in endpoint mode 30 min after addition of the
detection reagent and the fluorescence was used to calculate sample concentration
against the standard curve plotted using a linear regression. Standards and samples were
all run in duplicate and calculated concentrations were averaged from each well to determine sample concentration. Assay performance was verified by running quality control
samples alongside samples which were within 10% of the nominal concentration.
RNA Isolation and Quantitative PCR
RNA was isolated from the left ventricle using the mirVana isolation kit (AM1560,
Thermo Fisher) which isolates both total and small RNA. RNA was quantified and verified
for quality (260/280 > 1.8) using a NanoDrop One (Thermo Fisher). We used 1 μg of total
RNA, and iScript cDNA synthesis (Bio-Rad) to synthesize cDNA, which was then amplified
using SYBR green in a CFX qPCR instrument (Bio-Rad). We used 18s rRNA as an endogenous control. The primer sequences were: 18s (NR_003278), forward 5′GTAGTTCCGACCATAAACGA3′ and reverse 5′TCAATCTGTCAATCCTGTCC3′, and CBS
(NM_144855)

forward

5′TGCGGAACTACATGTCCAAG3′

and

reverse-

5′TTGCAGACTTCGTCTGATGG3′. The melting temperature for all reactions was 55 °C.
Results were analyzed by CFX Manager 3.0 software (Bio-Rad).
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Western Blotting
Protein was extracted from frozen portions of the LV by using RIPA buffer (RIPA,
BP-115D, Boston BioProducts, Ashland, MA) and a 2mL glass homogenizer. Protein lysates were quantified using a BCA protein assay kit (23227, Thermo Fisher). 30 µg of
proteins loaded onto 10 or 12% SDS PAGE gels.
All membranes were blocked using 5% nonfat dry milk in Tris-buffered saline (TBS)
at room temperature for 30 min. The primary antibodies used were: β-MHC (1:1000,
ab172967, Abcam), CSE (1:1500, H00001491-M02, Abnova), c-Fos (1:1000, 2250s, Cell
Signaling), total c-Jun (1:1000, 9165s, Cell Signaling), MMP9 (1:1000, ab119906, Abcam),
and TGF-β1 (1:100, sc146, Santa Cruz) for one hour . Secondary antibody incubation was
performed using: anti-mouse IgG-HRP, and anti-rabbit IgG-HRP (used at half the concentration of the respective primary antibody dilution, Cell Signaling). Restore Stripping Buffer
(46430, Thermo Fisher) was used as necessary. Protein expression was normalized
against total protein measured by Ponceau staining. Bands were visualized with a Clarity
Chemidoc (Bio-Rad), and band intensity and normalization were analyzed by ImageLab
software (Bio-Rad).
Histological Analysis
Tissue sections of mouse hearts were made for visualizing cell size and collagen
fibers. We made 5 μM transverse sections of hearts embedded in paraffin. We also performed wheat germ agglutinin (WGA) staining on 5 μm cryosections of the heart. Sections
were fixed in 4% paraformaldehyde and incubated in 5 μg/ml of WGA (W834, Thermo
Fisher) for 10 min at room temperature.
Sections were imaged using a VWR bright field microscope and Motic Images Plus
two imaging tool (Motic, Richmond, British Columbia). WGA sections were observed under
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a fluorescence microscope (EVOS, Life Technologies). We calculated perivascular and
interstitial (INT) fibrosis by quantifying % red pixels/total pixels in a uniform area using
Image J software. Exposure settings for imaging and thresholds for red pixel detection
were kept consistent for all images. Two random areas of the LV were chosen and the
same areas were imaged in all hearts. % fibrosis was averaged across the two areas to
determine interstitial fibrosis for each animal. For perivascular fibrosis, a similar diameter
vessel was identified in all sections and two random areas around the vessel were quantified for % fibrosis and averaged. Hypertrophy was quantified by manually counting the
number of cells in a uniform area of the image. Cells were counted in two randomly chosen
sections areas of the LV, which was kept consistent in all hearts, and averaged for each
animal.
In-situ Zymography
MMP activity was visualized in tissue sections by in-situ zymography. 5 μM transverse sections of the heart were made in a cryostat. Sections were incubated with fluorescein-conjugated DQ gelatin (D12054, Thermo Fisher), which yields highly fluorescent
peptides when digested by MMPs, for 1.5 hours at room temperature in the dark. After
washing in phosphate buffered saline, sections were fixed with 4% paraformaldehyde,
stained with DAPI for 5 min and mounted with a coverslip. Some sections were treated
with 1mM 1,10-phenanthroline monohydrate, an inhibitor of all MMPs, as a negative control.
Statistical Analysis
All statistical analysis was performed using GraphPad Prism 8 software. One-way
ANOVA and Tukey’s multiple comparisons was used to determine the statistical variance
between the four groups. A P-value of <0.05 was considered statistically significant and
individual P-values are shown for all graphs.
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RESULTS – I
Validation of Experimental Model Gravimetric Analysis
We confirmed CBS+/- mice by genotyping shortly after birth and by reduced gene
expression of CBS measured by qPCR of left ventricle tissue at the end of the experiment
(Figure 1.3). Serum concentrations of homocysteine in CBS+/- mice were approximately
twice the concentrations seen in WT mice, confirming the presence of mild HHcy in CBS+/mice (Figure 1D). At 12 weeks of age, WT control and CBS+/- mice were given a normal
chow control diet or a diet with orally active SG1002. The diet continued for 14-16 weeks
(Figure 1A) at which time the chest was opened to measure cardiac function, organs and
serum were removed, and wet organ weight was measured (Table 1.1). Heart weight was
significantly increased in CBS+/- mice which were normalized in CBS+/- mice were given
the SG1002 diet. Body weight and weight of other organs were unchanged between
groups.
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Figure 1.3: CBS+/- HHcy mice with H₂S Diet. A: Schematic of dietary schedule and cardiac function measurement. Mice were given an SG1002 supplemented or control diet at
12 weeks of age for 14-16 weeks. B: Representative genotyping of CBS+/- and WT mice.
C: Gene expression of CBS measured by real-time PCR shows reduced transcript levels
in the heart at the end of the experiment compared to WT. D: Homocysteine concentrations in serum were increased in CBS+/- mice compared to WT mice confirming CBS+/- mice
are a model of hyperhomocysteinemia. Bars expressed as mean±SEM with dots representing each animal. Unpaired student t-test was used for statistical analysis.
Previously published in (76).
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Table 1.1: Gravimetric Data from WT and CBS+/- mice with and without SG1002 diet
Parameter

WT

CBS +/-

CBS +/SG1002

Age (Days)

195±3.90

192±2.43

193±8.06

199±11.3

Body
Weight (g)

24.5±0.67

25.7±1.36

26.7±1.20

26.6±0.72

Heart
Weight (mg)

115±3.77

129±6.40*

116±4.87#

124±3.35

Liver Weight
(mg)

1030±102

973±57.0

881±44.3

978±38.8

Lung Weight
(g)

133±4.06

126±4.30

126±3.37

133±1.89

Kidney
Weight (mg)

148±5.68

160±4.59

139±4.69#

144±3.81

*P< 0.05 vs. WT. #P< 0.05 vs. CBS+/-

+

WT
SG1002

+
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HHcy and H₂S alters Transsulfuration Pathway
To determine if HHcy in CBS+/- mice and SG1002 H₂S donor diet induces changes
in the transsulfuration pathway, we measured serum concentrations of cysteine and H₂S
and expression of CSE (Figure 1.4). Cysteine, which is produced by CBS from homocysteine, showed slightly, but not statistically significant, decreased concentrations in CBS+/compared to WT mice. H₂S concentrations were also measured in serum at the end of the
experiment. H₂S concentrations were not reduced in CBS+/- mice; however, the SG1002
diet in these mice did significantly increase H₂S concentrations (Figure 1.4B). Protein
expression of the H₂S producing enzyme CSE was significantly increased in the left ventricle CBS+/- mice.

25

Figure 1.4: HHcy and SG1002 alter the transsulfuration pathway. A: Serum concentration (mM) of cysteine in CBS+/- and SG1002 treated mice at the end of the experiment.
No statistically significant difference was observed between groups. B: Serum H₂S did
not decrease in CBS+/- mice, but it was elevated by SG1002 diet. C: Representative and
quantified western blot analysis of CSE. Total protein from ponceau staining was used
as a loading control. The H₂S is producing enzyme CSE increases in CBS+/- mice. All
bars expressed as mean±SEM with dots representing each animal. One-way ANOVA
was used for statistical analysis. Previously published in (76).
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Improved Cardiac Fibrosis with H₂S in HHcy
To investigate whether CBS+/- mice develop cardiac fibrosis, we measured early
markers of remodeling and histological and molecular markers of fibrosis in the left ventricle. C-Fos and c-Jun protein expression in the left ventricle were significantly elevated in
CBS+/- mice compared to WT (Figure 1.5). SG1002 administration did not significantly
reduce this expression although there was a trend for decreased c-Jun expression compared to CBS+/- mice.
We found increased collagen deposition in the left ventricle of CBS+/- mice by
picosirius red, which stains all collagen types, indicating increased cardiac fibrosis (Figure
1.6A). This increase was limited to the interstitial myocardium and not the perivascular
area (Figure 1.6B).
In situ zymography, an assay for matrix metalloprotease (MMP) activity, was qualitatively increased in the left ventricle of CBS+/- mice compared to WT activity (Figure 1.6C).
Overlay of phase-contrast images with DQ gelatin stain from sections demonstrated that
DQ staining occurring mostly in the extracellular space and applying the MMP inhibitor
1,10-phenanthroline abolished all DQ signal confirming the specificity of the DQ staining
for MMP collagenase/gelatinase fibrotic activity.
Finally, molecular markers and pro-fibrotic mediators were measured. TGF-β protein expression was increased in the CBS+/- left ventricle (Figure 1.6D). MMP9 expression,
however, was not increased, indicating increased collagen deposition is likely due to an
increase in MMP activity rather than expression.
H₂S donor administration by diet mitigated the histologic and molecular signs of
cardiac fibrosis. Interstitial fibrosis normalized to WT levels in CBS+/- mice. MMP activity
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also decreased in CBS+/- + SG1002 mice to levels similar to WT. Finally, TGF-β protein
expression was restored to WT levels in CBS+/- given SG1002.

Figure 1.5: Signals of early cardiac remodelling are elevated in HHcy. A: Representative and quantified western blot analysis of c-Fos. Total protein from ponceau staining was used as a loading control. c-Fos expression increases in CBS+/- mice. B: Representative and quantified western blot analysis of c-Jun. Total protein from ponceau staining was used as a loading control. c-Jos expression increases in CBS+/- mice. All bars
expressed as mean±SEM with dots representing each animal. One-way ANOVA was
used for statistical analysis. Previously published in (76).
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Figure 1.6: Increased fibrotic remodeling in the HHcy heart is improved by H₂S. A:
Representative sirius red collagen staining in LV. The top panel shows interstitial area
and bottom panel shows perivascular fibrosis at 4x and 40x magnification. The same two
areas of the LV were assessed and averaged for interstitial fibrosis in all groups. Scale
bar = 200 μM. B: ImageJ quantification of sirius red collagen staining in the interstitial
area (left) and perivascular area (right). Interstitial fibrosis increased significantly in
CBS+/- mice which was reversed with SG1002 dietary treatment. Perivascular fibrosis is
reduced in WT mice with SG1002. C: In-situ zymography of left ventricular cryosections.
Green staining is DQ gelatin indicating MMP collagenase/gelatinase activity. Blue staining is DAPI nuclei stain. Scale bar = 100 μM. DQ staining overlaid with phase contrast
imaging of tissue suggests DQ staining occurs in the extracellular matrix. Use of 1,10phenanthroline general MMP inhibitor nearlyeliminated DQ staining. CBS+/- mice showed
increased DQ staining indicating increased MMP activity which was reduced by SG1002
treatment. D: Representative and quantified western blot analysis of TGF-β showed increased expression in CBS+/- mice which was reduced with SG1002 treatment. Total protein from ponceau staining was used as a loading control. E: Representative and quantified western blot analysis of MMP9 which was unaltered in all groups. Total protein from
ponceau staining was used as a loading control. All bars expressed as mean±SEM with
dots representing each animal. One-way ANOVA was used for statistical analysis. Previously published in (76).
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Improved Cardiac Hypertrophy with H₂S in HHcy
We subsequently measured histological and molecular markers of cardiac hypertrophy in CBS+/- mice with and without SG1002 diet. First, we measured cardiomyocyte
size in H&E and WGA stained sections of the left ventricle (Figure 1.7). CBS+/- mice sections showed fewer cells per uniform area measured, indicating greater cell size and cardiac hypertrophy. Similarly, heart weight to body weight ratio was increased in CBS+/- mice
compared to WT hearts (Figure 1.7). Finally, fetal/neonatal beta-cardiac myosin heavy
chain (β-MHC) is commonly re-expressed in the adult heart during cardiac hypertrophy
and remodeling. CBS+/- mice hearts showed increased protein expression of β-MHC,
providing further confirmation of cardiac hypertrophy in HHcy mice (Figure 1.7D). H₂S
donor diet normalized all signs of cardiac hypertrophy in CBS+/- mice. Cell size was reduced in H&E stained sections, heart weight to body weight ratio was reduced, and βMHC protein expression was reduced to levels comparable to WT hearts.
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Figure 1.7: Increased hypertrophic remodeling in the HHcy heart is improved by
H₂S. A: Representative and quantification of cardiomyocyte size by H&E staining. CBS+/mice showed cardiomyocyte hypertrophy (cells/ uniform area), which was normalized by
SG1002 treatment. Scale bar = 200 μM. B: Representative WGA staining of left ventricle
heart sections. Green color represents cardiomyocyte boundary and “∗” denotes a hypertrophied cardiomyocyte. Scale bar = 100 μM. C: SG1002 reduced heart weight/ body
weight (HW/BW) in CBS+/- mice. D: β-MHC, a marker of hypertrophy, was increased in
CBS+/- mice but was restored by SG1002 treatment. Total protein from ponceau staining
was used as a loading control. All bars expressed as mean±SEM with dots representing
each animal. One-way ANOVA was used for statistical analysis. Previously published in
(76).
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Alterations in Hemodynamic Function with H₂S
Cardiac function and hemodynamics were evaluated at the end of the experiment
using PV loop recordings to determine if the cellular remodeling alterations in HHcy mice
resulted in altered cardiac function (Figure 1.8). We evaluated measures of systolic and
diastolic function as cardiac remodeling affects diastolic function first (169). CBS+/- mice
exhibited increased end systolic pressure compared to WT mice but no change in enddiastolic or systolic volumes. Thus, stroke volume and cardiac output remained similar to
WT mice. This depicts a scenario of increased afterload but no decrease in systolic function. SG1002 restored the increased afterload in CBS+/- mice by reducing end systolic
pressure. Also, end-diastolic volume was significantly increased in CBS+/- + SG1002 mice
(Figure 1.8G) while end-systolic volume was unchanged. This resulted in increased stroke
volume in the CBS+/- + SG1002 group and suggested an increase in preload and ventricular filling.
Measures of diastolic function such as Tau and dp/dt min were unchanged between all groups. Load independent measures of cardiac function such as the end-diastolic PV relationship were not evaluated in this study.
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Figure 1.8: SG1002 treatment ameliorates increased afterload in CBS+/- mice. Representative PV loop measurement in A: Representative PV trace in WT, CBS+/-, and WT
mice treated with SG1002. B: Representative PV trace in CBS+/- mice treated with or
without SG1002. C: Heart Rate. D: Stroke volume. E: End-systolic pressure. F: End-systolic volume. G: End-diastolic volume. H and I: Measures of diastolic function (Tau and
dP/dt min) were unchanged between groups. Previously published in (76).
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SUMMARY OF RESULTS – I
While it is well established that HHcy increases the risk of CVD, the molecular
mechanisms of the effects of Hcy on the heart are less clear. Also, H₂S, a byproduct of
Hcy transsulfuration, may reverse these detrimental effects where folate has not. We investigated the effects of HHcy on the mouse heart in the CBS+/- model of HHcy and tested
whether H₂S can reverse these effects in vivo. Our results show that CBS+/- mice demonstrated multiple signs of early and late cardiac remodeling including fibrosis and hypertrophy, which culminated in increased afterload on the heart (Figure 1.9). Remodeling
changes were inhibited by dietary administration of the SG1002 H₂S donor to the mice for
~14 weeks and increased cardiac stroke volume. Our data further suggest H₂S reduces
TGF-β signaling in vivo to protect against cardiac fibrosis and hypertrophy.
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Figure 1.9: Working model for the amelioration of cardiac remodeling in HHcy by
H₂S. During pathological remodeling, transcriptional changes lead to inflammation and
cell death. Fibrosis formation and hypertrophy of cardiomyocytes follow to fill the growing
vacant extracellular space and leads to cardiac dysfunction. CBS+/- HHcy mice showed
alterations in the transsulfuration pathway and the molecular and histological signs of remodeling, fibrosis, and hypertrophy. H₂S supplementation with SG1002 inhibited these
alterations in pathological remodeling and reduced afterload on the heart. Previously
published in (76).
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DISCUSSION – I
Several studies have investigated the molecular effects of HHcy on vascular function, but few have studied cardiac remodeling and cardiac function (94, 153, 181). The
present study suggests that HHcy increases CVD risk in part because of cardiac remodeling, specifically increased cardiac fibrosis and hypertrophy. Our results agree with a
study by Raaf et al., which observed increased collagen deposition in the myocardium of
HHcy rats (140). This pathology also correlated with an increase in expression of the transcription factors and cytokines c-Fos, c-Jun, and TGF-β in HHcy mice. The master profibrotic cytokine TGF-β uses c-Fos and c-Jun in its signaling cascade to mediate TGF-βinduced transcription of genes that increase collagen deposition in the heart (82, 201). It
has also been shown that the TGF-β/c-Jun/c-Fos pathway alters MMP expression and
activity (113). Our study and the study by Raaf et al. showed similar increases in TGF-β
expression and MMP activity in the heart during HHcy.
Many types of cardiovascular diseases involving cardiac remodeling such as
DMCM also involve a cascade of inflammation, oxidative stress, and cell death, resulting
in fibrosis and compensatory cardiomyocyte hypertrophy (40, 104). It is possible in HHcy
that the cardiac remodeling we observed is because of inflammation, cell death, and oxidative stress on the heart rather than an effect of TGF-B signaling alone. In support of this
hypothesis, other studies of HHcy in the heart and liver demonstrate increased oxidative
stress and increased pro-apoptotic Bax protein expression (24, 143).
Previous studies have not however determined if remodeling manifests in alterations in cardiac function. In our study, CBS

+/-

mice did not show a drastic deterioration of

cardiovascular function, aside from an increase in afterload (increased end systolic pressure with conserved stroke volume) on the heart and did not show functional signs of
cardiomyopathy even though they showed abnormal cardiac fibrosis and hypertrophy.
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Studies have shown alterations in vascular function and more notably hypertension in
HHcy (152). Hcy has been shown to cause endothelial injury directly, promote atherosclerotic lesion formation, and reduce nitric oxide (NO) availability, all of which can induce
hypertension (152, 181). The increased afterload on the heart may be due to these arterial
changes. It is also likely that an additional hit is necessary for HHcy to induce more drastic
functional cardiovascular alterations such as decreased diastolic function. For example, it
appears that diabetes acts synergistically with HHcy to accelerate the development of
cardiomyopathy (122). Other techniques such as load independent PV loop measurements or cardiac MRI may be more sensitive to detect early alterations in cardiac function.
We hypothesized that H₂S, a metabolite of Hcy, could mitigate the effects of HHcy
in vivo. H₂S is cardioprotective against fibrosis and hypertrophy in models of HHcy, ischemia/reperfusion, and diabetic cardiomyopathy (8, 123, 190); however, in vivo validation of
these data is limited. We found that increasing circulating concentrations of H₂S by dietary
administration of a slow release H₂S donor, SG1002, normalized the molecular and histological measurements of fibrosis and hypertrophy. H₂S significantly reduced collagen deposition in the left ventricle of HHcy mice, reduced MMP activity, reduced cardiomyocyte
size, and heart weight normalized to body weight. H₂S did not normalize c-Fos and c-Jun
expression, however, it did significantly reduce TGF-β expression. Thus, the cardioprotective effects of H₂S in HHcy may still be due to its effects on TGF-β signaling. In rat
models of hypertension, H₂S donors similarly reduced collagen remodeling in the heart
which was associated with effects on TGF- β signaling (115, 165). The cardioprotective
benefits of H₂S may also be due to its role in signaling of inflammation, oxidative stress,
cell death, and master transcription factors (55, 74, 166, 205). For instance, an in vitro
study by Yang et al. demonstrated in fibroblasts that H₂S sulfhydrated Keap1 to activate
the Nrf2 transcription factor, production of the antioxidant glutathione, and protected cells
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for early death (196). Further studies are necessary to determine the mechanisms of H₂S
mediated cardioprotection in HHcy.
Functionally, increasing H₂S normalized the increased afterload observed in HHcy
mice and increased stroke volume suggesting an increase in preload. While it is unclear
why preload and ventricular filling would be enhanced in this group, we hypothesize that
these effects may also be due to vascular changes from the systemic H₂S donor. H₂S has
been shown to reduce vascular smooth muscle cell proliferation (195), increase NO production in vascular smooth muscle cells (68), and inhibited angiotensin-converting enzyme
(ACE) activity of endothelial cells (92).
It is important to note that we expected H₂S and cysteine levels to decrease in
HHcy CBS+/- mice since CBS deficient mice cannot transsulfurate Hcy into H₂S. In fact, in
the rat liver and heart in HHcy, H₂S levels were decreased due to decreased CSE activity
(99, 198). In our study, however, H₂S and cysteine levels in serum were unchanged in
HHcy. We attribute this to the compensatory increase in tissue level CSE expression
which is consistent with our previous in vitro data (123). Thus, in our study CBS deficient
mice developed cardiac remodeling, presumably by altered Hcy levels itself or possibly a
local change in H₂S concentrations that were not measured in this study. Elevating H₂S
in HHcy prevents these effects, which suggest a clinical benefit of H₂S in HHcy where
trials of administering folate in HHcy have provided no benefit.
In conclusion, we demonstrate that H₂S prevents cardiac remodeling induced by
HHcy in vivo and induces molecular alterations in TGF-β expression and MMP activity.
These results suggest that H₂S may be a preventative treatment for cardiac remodeling
and in patients with HHcy and in conditions where Hcy is elevated such as in diabetic
patients with DMCM.
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CHAPTER 2: HYDROGEN SULFIDE TRANSCRIPTIONALLY REGULATES CARDIAC
AUTOPHAGY AND PYROPTOSIS
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INTRODUCTION – II
Chapter 1 observed pathological cardiac remodeling in the CBS+/- model of HHcy
with deficient H₂S biosynthesis, which demonstrated the importance of H₂S biosynthesis
in the pathophysiology of cardiomyopathy. H₂S donor treatment prevented in vivo remodeling, demonstrating the cardiovascular physiological benefits of H₂S supplementation.
However, the mechanisms by which H₂S prevents cardiac remodeling were unclear. Previous in vivo studies suggest H₂S can improve cardiac structure and function by inhibiting
cell death, vascular effects, and regulation of calcium and potassium homeostasis. (184)
As described previously, cell death is a primary driver of cardiac remodeling in
DMCM due to the effects of the toxic diabetic microenvironment in cardiomyocytes. Because of the previously mentioned co-morbidity between HHcy and DMCM and the observations of aberrant H₂S biosynthesis in DMCM, we hypothesized the prevention of cardiac fibrosis and hypertrophy signaling that we observed in HHcy CBS+/- by H₂S donor
treatment is due to prevention in cell death. While H₂S has been shown to regulate apoptosis and necrosis in vivo, less is known about how H₂S regulates pyroptosis and autophagy associated cell death. GYY4137, a H₂S donor, treatment mitigates endoplasmic reticulum (ER) stress, pyroptosis, and improves visual function in the CBS+/- mice (49). CBS-/mice, a severe hyperhomocysteinemia model, induces caspase-1 activation along with
other pyroptosis markers determined by flow cytometry gating in isolated lung endothelial
cells and in aortic endothelium (189).
Pyroptosis (Figure 2.1) is a unique form of cell death in which the canonical pathway is specifically dependent on caspase-1, and the non-canonical pathway is reliant on
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caspase-11 (12). The nod-like
receptor protein 3 (NLRP3) inflammasome is charged with
activating caspase-1 in the canonical

pyroptosis

pathway.

Blocking the inflammasome has
been shown to mitigate cardiac
remodeling

post-infarction

(111).

activated

IL-18

by

caspase-1 has been shown to

Figure 2.1: Inflammasome mediated pyroptosis
results in cell rupture.

induce cardiac hypertrophy by
increasing atrial natriuretic peptide (ANP) (114). Elevated serum levels of IL-1β, a second
inflammatory cytokine downstream of the pyroptosis pathway, has also been reported
post-MI and in patients with cardiomyopathy (53).
A limited number of studies have shown a role of H₂S signaling in pyroptosis in
other organs and in pathological conditions. To date, only one study has reported a role
for H₂S in pyroptosis in the heart. Toldo et al. demonstrated that an H₂S donor suppressed
several pyroptosis activity markers (caspase-1 activity, caspase-1 recruitment via the ASC
adapter protein) in an I/R cardiomyopathy model (171). The role of pyroptosis in cardiomyopathies and the mechanistic role of sulfide signaling in pyroptosis requires further
studies.
Autophagy is a cellular homeostatic mechanism of clearing damaged or unnecessary organelles and macronutrients by lysosomal degradation (191). An optimal window
of autophagy maintains homeostasis in response to cardiovascular events while excessive
or deficient autophagy becomes maladaptive, leading to increased cell death known as
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autophagy associated cell death. Autophagy can significantly inhibit pyroptosis by clearing
NLRP3 activating danger associated molecules such as damaged mitochondria.(54) The
nutrient-sensing mTOR complex 1 (mTORC1) integrates metabolic signals from AMPK
and insulin, and when activated, mTOR inhibits the initiation of autophagy. Oxidative and
nitrosative mechanisms have been shown to regulate autophagy in cardiomyopathies, and
recent evidence shows the importance of H₂S signaling in this process. (178) In smokinginduced cardiomyopathy, H₂S administration decreased autophagy (204).
Hypothesis and Aims
H₂S has also been shown in vitro to inhibit cell death by transcriptional regulation.
For example, H₂S has been shown to sulfhydrate the p65 subunit of NF-kB, a key regulator
of pyroptosis signaling, and increase the transcription of anti-apoptotic gene targets TRAF,
cIAP-2, Bcl-XL, and XIAP (150). Ablation of CSE and reduction of H₂S abolished these
beneficial effects. However, in vivo data demonstrating H₂S regulates transcription of cell
death associated genes in the heart is limited. We hypothesized that H₂S prevents cardiac
remodeling in CBS+/- mice by transcriptome regulation of pyroptosis and autophagy (Figure 2.2). To determine the transcriptional changes induced by H₂S donor treatment, we
performed non-biased deep RNA sequencing (RNAseq) of mRNA, and non-coding RNA
in the left ventricle of SG1002 treated CBS+/- mice.

Figure 2.2: Research Goal II Hypothesis. We hypothesized the improved cardiac remodeling with H2S donor treatment in the model of aberrant H2S biosynthesis is due to transcriptome regulation of cell death.
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METHODS – II
Experimental Models and H₂S Donor Diet
This study utilized the WT, CBS+/-, CBS+/- + SG1002, and WT + SG1002 mice with
the SG1002 H₂S donor diet from Chapter 1: Experimental Models and H₂S Donor Diet
of this dissertation. A portion of the left ventricle (LV) previously flash frozen was used for
molecular and expression analysis in this study.
RNA Sequencing (RNAseq)
For RNAseq, total RNA was isolated using Ambion Trizol Reagent (Fisher Scientific, Cat # 15-596-018). RNA cleanup was done by using Direct-Zol RNA kit (Zymo Research Cat # R2060). Quantity and purity was determined by Nanodrop. RNA quantity
was reconfirmed by Quant-iT™ Qubit RNA BR Assay Kit (Fisher Scientific Cat # Q10210)
and average of Nanodrop and Qubit was used to determine RNA concentration. Quality
of RNA was determined using Agilent Bioanalyzer RNA 6000 Nano kit (Agilent Technologies Cat # 5067-4626). RNA with RNA integrity number (RIN) > 7 was used for downstream application (Supplmentary Figure S1). RNA-seq was conducted utilizing commercial services from Epigenuity LLC (Loma Linda, CA). Briefly, RNA was mixed with ERCC
ExFold RNA Spike-In Mixes (Life Technologies, Cat # 4456739) as a control. Ribosomal
RNA was removed using RIBOMINUS EUKARYOTE SYSTEM V2 (Thermo Fisher, Cat #
A15026). Dynabeads® MyOne™ Streptavidin C1 beads (Thermo Fisher Cat# 65002) was
used to remove the purified RNA. Following removal of ribosomal RNA successful removal
was confirmed by using Agilent Bioanalyzer RNA 6000 Pico kit (Agilent Technologies Cat
# 5067-1511). Agilent electropherogram showed the disappearance of both 18s and 28s
ribosomal peak (Supplementary Figure S2). The remaining RNA was quantified by Qubit®
RNA HS Assay Kit (Thermo Fisher, Cat # Q32852). RNA libraries for deep sequencing

43
were prepared using Ion Total RNA-Seq Kit v2 (Thermo Fisher Cat # 4475936). Dynabeads® MyOne™ Streptavidin C1 beads (Thermo Fisher Cat# 65002) was used to remove the purify RNA library. Library concentration was determined by using Qubit™
dsDNA HS Assay Kit (Fisher Scientific Cat # Q32584) and Agilent High Sensitivity DNA
Kit (Agilent Cat # 5067-4626). The library was loaded on Ion 540 Chip (Thermo Fisher Cat
# A27766) using Ion Chef 540 Chef Kit reagents (Thermo Fisher Cat # A27759). About 80
million single end 200 basepair reads were generated for each sample. Raw Fastq files
were obtained and Quality Check was conducted using Fastqc Software (Babraham Institute, Cambridge, UK). Low quality reads/bases were trimmed using Trimmomatic Software
(USADEL Lab org, Germany). Reads were aligned to the MM10 genome using STAR
alignment software (Center for Computational Biology, John Hopkins University). Aligned
files were further analyzed using Seqmonk software (Babraham Institute). RNA-QC plots
were generated to examine ribosomal percent, mitochondrial percent, gene alignment,
and other parameters. RNA-seq analysis was conducted on Seqmonk, and raw counts
were generated.
Real-time PCR validation
RNAseq analysis results were validated by real-time PCR (qPCR). We chose top
upregulated and downregulated genes for qPCR analysis. RNA was isolated from a portion of the LV using the Protein and RNA Isolation System, PARIS™ (ThermoFisher). 600
ng of RNA was used to synthesize cDNA using the iScript™ cDNA Synthesis Kit (Bio-rad).
The pre-validated TaqMan® gene expression primer and probe sets (ThermoFisher) used were: 18s: Mm03928990_g1; HalR1: Mm04411625_m1; Foxo6os:
Mm01720641_m1; Dnahc8: Mm01299527_m1; Sdf2l1: Mm00452079_m1; NLRP3:
Mm00840904_m1. Relative expression was normalized to 18S RNA, and fold-changes
were calculated using the ΔΔ CT. Samples were analyzed on the CFX Connect Real-Time
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PCR Detection System (Bio-Rad) using the TaqMan universal master mix II (ThermoFisher) with 2ul of cDNA in a 20 ul reaction mixture.
Ingenuity Pathway/Network Enrichment Analysis
We analyzed the annotated genes using Ingenuity Pathway Analysis (IPA) Program (Ingenuity Systems, Redwood City, CA) to identify enriched biological pathways. Zscore was calculated to examine the activation or inhibition status of a particular pathway
in the present dataset against the IPA knowledge database. Z-score of > 2 or < -2 was
considered significant. IPA predicted the canonical pathways, diseases and functions, and
signaling networks altered in the transcriptome from the dataset. Upstream regulator analysis was conducted to identify upstream signal transduction regulators that can mimic the
observed gene expression changes in the present dataset.
Western Blotting
Protein from LV tissue was isolated alongside RNA isolation with the PARIS kit
described above. Western blotting of proteins involved in the biological pathways identified
by IPA (particularly pyroptosis and autophagy) were probed as described in Chapter 1:
Western Blotting.

Antibodies used were: IL-1β (1:1000, 52718S, Cell Signaling),

Caspase-1 (1:1000, ab1872, Abcam), NLRP3 (1:1000, NBP2-12446, Novus), Gasdermin
D (1:1000, ab209845, Abcam), NF-kB phosphor-p65 (1:1000, ab86299, Abcam), beclin 1
(1:1000, 3495s, Cell Signaling), LC3B (1:1500, ab51520, Abcam), SQSTM1 / p62 (1:2000,
ab56416, Abcam), mTOR (1:1000, 2983s, Cell Signaling). The secondary antibodies used
were anti-mouse IgG-HRP, and anti-rabbit IgG-HRP (used at half the concentration of the
respective primary antibody dilution, Cell Signaling)
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Immunofluorescence
Expression of pyroptosis effector proteins was visualized in heart tissue sections
by immunofluorescence as described previously.(194) 5 μM transverse sections of the
heart were made in a cryostat. Sections were incubated with IL-18 (Abbiotec, 251182,
1:100) or caspase 1 primary antibody overnight at 4C followed by red fluorescent secondary antibody and DAPI counterstain.
Autophagic Flux
Assessment of functional autophagy was performed by measuring autophagic flux
in cardiomyocytes with terminal inhibition of autophagosome degradation with bafilomycin
A1. We cultured HL1 mouse atrial cardiomyocytes (Sigma) following established protocols.(27) At 70–80% confluency cells were treated with 100 uM Hcy (cat # H4628, Sigma,
USA) with or without 100 uM GYY4137, a cell culture suitable, water soluble slow releasing H₂S donor (cat # 13345, Cayman Chemical) for 24 hours. Two hours prior to protein
lysis, cells were treated with 150 nM bafilomycin A1 or DMSO control. Total protein was
isolated using 200 ul RIPA buffer (BP-115D, Boston BioProducts, Ashland, MA). Protein
lysates were quantified using a BCA protein assay kit (23227, Thermo Fisher). 30 µg of
proteins loaded onto 12% SDS PAGE gels for western blotting of LC3-II.
Statistical Analysis
Differential gene analysis for RNAseq was conducted using DESeq2 package on
R-Statistical Software. The Benjamini-Hochberg (BH) adjusted p values were calculated
to adjust for multiple-testing caused false discovery rate. Statistical significance in the realtime PCR and western blotting data was determined by one-way analysis of variance
(ANOVA) and post-hoc Newmans-Keul test using GraphPad Prism 8.
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RESULTS – II
Aberrant H₂S Biosynthesis and SG1002 Alter the Cardiac Transcriptome
We compared RNAseq datasets of the four mouse groups to examine the effect of
deficient H₂S biosynthesis and SG1002 donor treatment on cardiac gene expression. On
applying negative binomial Walt Test using DESeq2 statistical package, we observed
2043 genes with p-value < 0.05. On further application of Benjamin-Hochberg test, we
adjusted the p-value to reduce the False Discovery Rate < 0.05 and identified 205 genes
below FDR 0.05. Of these 205 genes with FDR below 0.05, 79 were upregulated more
than 1.5-fold and 22 were downregulated more than 1.5-fold
Figure 2.3 lists top genes that were upregulated and downregulated in CBS+/- and
CBS+/- + SG1002 mice. We validated one mRNA with qPCR from each comparison group.
Dnahc8 (T complex distorter 2) increased in CBS+/- but did not decrease with SG1002 diet
matching the RNAseq data (Figure 2.2 C). Similarly, Sdf2l1 (stromal cell-derived factor 2like 1), a regulator of endoplasmic reticular stress, was unchanged in CBS+/- mice compared to WT mice but increased with SG1002 diet, confirming the RNAseq data.
RNAseq also indicated that several long non-coding RNA (lncRNA) were altered
in the LV. We confirmed the differential expression of the lncRNA with annotated gene
names in the LV with qPCR. Halr1 (Hoxa adjacent long non-coding RNA 1) showed a 3.9
fold increase in CBS+/- vs. WT with RNA seq. Gene expression measured by qPCR
showed a ~3 fold increase but was not statistically significant (Figure 2.2 E). Forkhead
box O6, opposite strand lncRNA (Foxo6os) decreased in RNAseq and significantly decreased in CBS+/- + SG1002 compared to CBS+/- mice measured by qPCR.
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Figure 2.3: Transcriptome alterations in the HHcy heart after SG1002 H₂S Donor
Treatment. A: Top genes upregulated or downregulated in the HHcy LV (CBS+/-) compared to WT LV determined by RNAseq. B: Top genes upregulated or downregulated in
the HHcy LV treated with SG1002 H₂S donor (CBS+/- + SG1002) compared to the HHcy
heart. C-D: Validation of Dnahc8 and Sdf2l1 mRNA by qPCR identified as top altered
genes. E-F: Validation of Halr1 and Foxo6os lncRNA by qPCR identified as top altered
genes. All bars expressed as mean±SEM with dots representing each animal. One-way
ANOVA followed by Tukey test was used for statistical analysis.
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H₂S Regulates Cell Death and Cell Survival Pathways
We performed IPA analysis to determine biological pathways altered in the CBS+/+ SG1002 RNAseq dataset compared to CBS+/- mice. The CBS+/- + SG1002 LV gene
expression profile was predicted to show altered cardiac hypertrophy and cardiac dysfunction (Figure 2.4A). IPA predicted directional changes in cell death with 133 genes
consistent with a decrease in necrosis, 119 genes consistent with a decrease in apoptosis,
and 157 genes that increase cell survival with SG1002 diet treatment. Further network
analysis predicted SG1002 diet decreases mTOR signaling, an inhibitor of autophagy, and
decreases Nf-KB, an activator of pyroptosis (Figure 2.4C). This was supported by network
analysis showing alterations in genes that inhibit pyroptosis (Figure 2.5D) and inhibition
of IL-1β produced by pyroptosis. Finally, network analysis predicted mTOR inhibition by
transcriptional changes increases autophagy with SG1002 diet treatment (Figure 2.5B).
H₂S Reduces Pyroptosis Signaling Activation
Because IPA analysis indicated a decrease of cell death and specifically pyroptosis
with SG1002 treatment, we evaluated the three primary steps of pyroptosis: 1) inflammasome production and formation, 2) activation of the inflammasome assessed by activation of caspase-1, and 3) activation of the cell lysis inducing gasdermin d (GSDMD).
NLRP3 inflammasome gene and protein expression was increased in CBS +/- mice (Figure
2.6A-B). In addition, we observed an increase in the cleaved activated form of caspase-1
in the LV of CBS

+/-

(Figure 2.6C), suggesting both increased production and activity of

the inflammasome. The cleaved effector molecules of pyroptosis GSDMD and IL-1β also
showed increased expression of their cleaved activated forms in CBS

+/-

mice. Caspase-

1 and IL-18 were also elevated in LV tissue of CBS +/- mice when visualized with immunohistochemistry (Figure 2.6A). Finally, cardiac expression of the p65 subunit of NF-kB,
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which transcriptionally regulates pyroptosis and NLRP3 expression, increased in CBS

+/-

mice.
SG1002 donor treatment in CBS+/- normalized expression of NLRP3, cleaved
caspase-1, cleaved GSDMD, IL-1β, NF-kB. Tissue staining of caspase-1 and IL-18 were
also reduced in the CBS+/- + SG1002 heart (Figure 2.7B).
H₂S Restores Adaptive Autophagy
We measured in vivo markers of autophagy and in vitro autophagic flux to validate
the IPA prediction that SG1002 treated mice show increased adaptive autophagy and thus
cell survival. CBS +/- mice showed decreased protein expression of the autophagosome
initiation protein Beclin 1 in LV tissue (Figure 2.8A). LC3B-II, a marker of autophagosomes,
was also decreased in CBS +/- mice. p62/SQSTM1, a marker of autophagosome degradation, was elevated in CBS +/- mice indicating an accumulation of autophagosomes not
yet degraded. Expression of the negative regulator of autophagy, mTOR, was increased
in CBS +/- mice heart. SG1002 treatment in CBS +/- mice increased cardiac levels of
Beclin 1, and LC3B-II,but decreased p62, and mTOR.
Appropriate interpretation of alterations in autophagic compartments requires evaluating the passage of materials through the entire system.(120) We assessed the dynamic
autophagic flux process in vitro to determine if an alteration in steady-state abundance is
due to increased formation (increased flux) and/or decreased clearance (decreased flux).
LC3B-II expression was compared after bafilomycin (baf) inhibition of autophagosome
degradation in HL-1 cardiomyocytes were treated a Hcy and GYY4137 H₂S donor. LC3-II
expression decreased in baf- treated cardiomyocytes with Hcy treatment compared to baftreated cardiomyocytes without Hcy treatment. GYY4137 treatment in Hcy treatment
groups normalized LC3B-II expression (Figure 2.8E). This indicates decreased autophagic flux in HHcy is restored to normal levels with H₂S donor treatment. Together, this
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data indicates an in vivo decrease in the autophagy process in the LV of HHcy CBS +/mice. In agreement with IPA analysis, these functional data demonstrate SG1002 restores
deficient autophagy in HHcy.
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Figure 2.4: Ingenuity pathway analysis of transcriptome in the HHcy heart after
SG1002 H₂S Donor Treatment. A: Significantly altered canonical pathways in CBS+/- +
SG1002 LV compared to CBS+/- as baseline shows enrichment of genes essential in
cardiac remodeling and cell death. B: Diseases and functions analysis predicted inhibition of cell death pathways and activation of cell survival viability. Each box represents
one signaling pathway. C: Canonical pathway analysis also indicated SG1002 inhibited
upstream regulators of cell death and survival, such as inhibition of mTOR (an inhibitor
of adaptive autophagy) and inhibition of NF-kB, a transcriptional activator of pyroptosis.
D: Network pathway analysis predicted H₂S treatment inhibits multiple cell death pathways in CBS+/- mice, including apoptosis and pyroptosis. E: Inhibited IL-1β, which is produced by pyroptosis, in the H₂S treatment group is predicted to be an upstream regulator
of downstream transcriptional changes.
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Figure 2.5: Transcriptome alterations in the HHcy heart after H₂S treatment predict
functional enrichment of cell survival, adaptive autophagy, and metabolism. A:
Diseases and functions ingenuity pathway analysis predicted functional alterations in cell
death, cell survival, and lipid metabolism with SG1002 donor treatment. B: Network
analysis further predicted H₂S treatment in HHcy activated autophagy via inhibition of
the autophagy inhibitor mTOR. C: Transcriptome alterations also predict an alteration of
fatty acid metabolism by H₂S.
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Figure 2.6: H₂S Inhibits Increased Pyroptosis Signaling in the HHcy Heart. A-B:
NLRP3 inflammasome gene and protein expression is elevated in the LV of CBS+/- mice
and reduced by SG1002. C: Caspase-1, which is activated by the inflammasome,
showed higher activation (cleaved caspase-1) in CBS+/- mice and reduced by SG1002
D: Gasdermin D, the final effector of pyroptotic cell death produced by caspase-1 cleavage also showed higher activation (cleaved gasdermin D) in CBS+/- mice and reduced
by SG1002 E: Inflammatory active IL-1β produced by caspase-1 cleavage (cleaved IL1β) is also reduced by SG1002. F. Expression of the p65 subunit of NF-kB which initiates transcription of NLRP3, was reduced by SG1002. All bars expressed as
mean±SEM with dots representing each animal. One-way ANOVA was used for statistical analysis.
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Figure 2.7: Representative Immunofluorescence of pyroptosis components after
SG1002 treatment. Caspase-1 (A) and IL-18 (B) staining (red) increased in the LV of
CBS+/- mice and was reduced with SG1002 treatment. Scale bar = 100 uM
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Figure 2.8: H₂S Restores Autophagic Flux in the HHcy Heart. A: SG1002 slightly upregulated Beclin-1 expression which initiates autophagosome formation. B: LC3B-II, a
marker of autophagosome formation was slightly reduced in CBS+/- mice and increased
by SG1002. C: p62, which is reduced by autophagosome degradation, accumulated in
CBS+/- mice denoting deficient autophagy. SG1002 treatment reduced p62 expression
denoting increased autophagy. D: mTOR, which inhibits beclin 1 in autophagosome formation, is normalized by SG1002. E: GYY4137 treatment improved the reduction in autophagic flux in Hcy treated cardiomyocytes. LC3B-II expression was reduced in HL1
mouse cardiomyocytes treated with Hcy (100 uM) compared to control cells. The H₂S
donor GYY4137 (100 uM) increased flux in Hcy treated cells. Cells were treated with
bafilomycin (150 uM, Baf) for two h to assess flux (Two-way ANOVA).
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SUMMARY OF RESULTS – II
We performed full transcriptome sequencing of CBS +/- mice hearts treated with
SG1002 to determine how H₂S prevents HHcy induced cardiomyopathy seen in our previous studies.(76) We observed that SG1002 induced significant transcriptome changes
to mRNA and non-coding RNA. This led to functional changes of decreased pyroptosis, a
non-apoptotic form of cell death, and increased autophagy, an adaptive cell survival process predicted by IPA, and confirmed by in vivo studies.
IPA algorithm analysis indicated that cardiac function and hypertrophy were the primary disease functions altered transcriptionally by SG1002. Moreover, it
predicted that these changes were
associated with decreased cell
death and increased cell survival
by SG1002. This follows the physiological mechanisms of cardiac
remodeling, where cell death precedes cardiac fibrosis. Our func-

Figure 2.9: H2S prevents cardiac remodeling
by reducing pyroptotic cell death and simultaneously increasing autophagy. In vivo transcriptome alterations in the left ventricle in HHcy
showed a functional increase in pyroptotic cell
death signaling and decreased adaptive autophagy which were confirmed by protein expression
analysis. SG1002 H2S donor treatment reduced
pyroptosis and increased autophagy which would
prevent pathological cardiac remodeling in HHcy.

tional studies in the left ventricle focused on pyroptosis and autophagy because IPA identified the top networks of NF-kB, IL1B, and mTOR which are key components of pyroptosis autophagy. We propose a working model where H₂S inhibits cardiac remodeling my decreasing pyroptosis and increasing
adaptive autophagy (Figure 2.9).
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DISCUSSION – II
Our protein analysis data showing a decrease in NLRP3 gene expression and a
decrease in mTOR expression suggest H₂S regulates these processes by transcriptome
regulation. To this effect, activated NF-kB, which activates transcription of inflammasome components,(12) was decreased with SG1002 diet. Our data is supported by
previous studies showing H₂S activates protective anti-apoptotic effects of NF-kB (150)
by sulfhydration of p65. In the liver, sulfhydrated p65 increases expression of anti-apoptotic gene targets such as TRAF, cIAP-2, Bcl-XL, and XIAP (150).
In addition to decreased pyroptosis, amelioration of cardiac remodeling in CBS +/mice by SG1002 may be due to a restoration of adaptive autophagy. While primarily a
protective cellular mechanism, autophagy can lead to cell death if autophagic activity is
abnormally increased or decreased, as we observed in CBS +/- mice, known as autophagy associated cell death.(120) Moreover, it is possible that deficient autophagy in CBS
+/- mice can indirectly increase pyroptosis by causing a build-up of inflammasome activating components such as damaged mitochondria. Interestingly, increased pyroptosis can
decrease autophagy when caspase-1 cleaves and deactivates the autophagy activator
TRIF.(155, 192, 193) These cross-talk mechanisms between pyroptosis and autophagy
likely play a role in the HHcy induced remodeling we observed. Further investigation may
reveal a novel action of H₂S to regulate cross-talk between these cell death pathways.
We also observed several lncRNA were altered by H₂S donor diet. Of those identified in RNAseq and confirmed by qPCR, very little is known about the function of these
lncRNA in the heart. only Foxo6os has been shown to have a possible role in diabetes
as an altered lncRNA in diabetic skeletal muscle – however no function of the lncRNA
was studied.(200) lncRNA regulation, may be a potential mechanism of H₂S prevention
of cell death. To our knowledge, there is no study testing whether H₂S affects lncRNA
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expression. However, recent studies showing lncRNAs regulate cardiomyocyte cell
death (27, 164) provide a rationale for determining whether H₂S could modulates cell
death via lncRNA.
This study suggests that H₂S may be a preventative treatment for cardiac remodeling and in patients with HHcy and in conditions where Hcy is elevated such as in diabetic patients with DMCM. To date, only one rat study has shown H₂S donors prevent
DMCM.(205) Additional in vivo rodent studies are necessary to determine whether and
how H₂S donors prevent cell death, promote cell survival, and prevent cardiac remodeling in DMCM.
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CHAPTER 3: HYDROGEN SULFIDE PROTECTS AGAINST CARDIAC FERROPTOSIS IN DIABETIC CARDIOMYOPATHY
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INTRODUCTION – III
Diabetic cardiomyopathy (DMCM), a diabetes mellitus (DM)-induced cardiac muscle disorder that can progress to heart failure, affects about 20% of otherwise healthy DM
patients.(30) While it is believed that hyperglycemia in DM leads to cardiac remodeling
and ultimately heart failure,(3) intensive glycemic control does not reduce the risk of heart
failure.(14, 22) Some DM medications are also contraindicated.(125) These complications
have led to a mortality rate of 30% for DMCM.(30) New approaches are needed to understand, diagnose, and target the pathogenesis of DMCM.
Death of terminally differentiated cardiomyocytes due to the diabetic environment
in leads to loss of contractile units, compensatory hypertrophy and fibrosis, and a progression to heart failure.(17) Targeting cell death has proven effective to prevent DMCM in
rodents.(93, 108) Currently, 12 distinct forms of cell death have been identified.(43) While
apoptosis and necrosis are well established in the DM heart,(18) there is a lack of understanding of other cell death forms. Non-apoptotic forms of cell death must be studied and
targeted since inhibition of one cell death pathway can lead to compensation by other
forms of cell death.(18)
Ferroptosis is a regulated cell death process first reported in cardiomyocytes only
in the last 4 years.(38, 46, 64) It is morphologically and functionally unique from apoptosis
and necrosis.(38, 162) In pathological conditions, intracellular iron drives reactive oxygen
species (ROS) production in the cytosol and mitochondria (Figure 3.1).(20, 47) This iron-
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mediated ROS targets membrane and intracellular lipids to form lipid peroxides,
which induce cellular damage, and ultimately death.(34, 35) Ferroptosis is limited
by the antioxidant glutathione peroxidase
4 (GPX4) which utilizes GSH to prevent lipid peroxidation.(162) Cysteine, produced
by methionine transsulfuration, is used to
synthesize GSH, and is thus also a regulator of ferroptosis.(197) While the role of ferroptosis is unclear, clinical evidence
strongly links iron metabolism to DMCM.

Figure 3.1: Ferroptosis Pathway. GPX4,
which removes polyunsaturated fatty acid
(PUFA) lipid peroxidation catalyzed by
iron, is the primary regulator of ferroptotic
cell death. Transsulfuration pathway produces H2S, and H2S regulates the substrates of GPX4 (green arrows). But it is
unknown how H2S regulates ferroptosis.

Cardiomyopathy is a cardinal symptom of
patients with hereditary iron overload.(168) Moreover, hyperinsulinemia in DM stimulates
intracellular iron uptake, which would be predicted to increase ferroptosis.(39) Suzuki et
al. demonstrated lipoxygenases, which enzymatically oxidize lipids, is elevated in the
hearts mice with DMCM, but did not determine whether this as linked to increased ferroptosis.(167) Investigating the mechanisms of ferroptosis will enhance our understanding of
and options to inhibit cell death in the DM heart.
Deficiency of hydrogen sulfide (H₂S), a cardioprotective gas, contributes to
DMCM.(199) While there is one in vivo report showing H₂S donor treatment prevented
DMCM in a rat DMCM model,(97) and in vitro reports showing H₂S prevents cell death in
hyperglycemia treated cardiomyocytes,(74, 205) more in vivo studies are needed to determine how H₂S prevents DMCM by inhibition of cell death. We have previously shown
H₂S donor treatment in HHcy, a co-morbidity of DMCM, prevents cardiac remodeling in
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vivo (76) and prevents non-apoptotic cell death signaling such as pyroptosis and autophagy associated cell death (Hydrogen Sulfide Transcriptionally Regulates Cardiac Autophagy and Pyroptosis).
Growing evidence suggests H₂S regulates the signaling pathway of ferroptosis.
H₂S is endogenously produced during cysteine synthesis, the precursor for the antioxidant
glutathione (GSH), and H₂S donors increase intracellular GSH. Membrane GSH is a substrate for glutathione peroxidase 4 (GPX4), which removes lipid peroxidation and is the
primary inhibitor of ferroptosis. H₂S also regulates Nrf2, a transcriptional regulator of
GPX4.(61) However, no study has investigated the role of H₂S in ferroptosis.
Hypothesis and Aims
We hypothesized that ferroptosis is
increased in the diabetic heart to promote
cell death and instigate DMCM, which is
ameliorated by restoring H₂S levels (Figure
3.2). We assessed cardiac ferroptosis in
db/db mice exhibiting DMCM and db/+ (WT)
hearts. To determine whether H₂S inhibits
cardiac ferroptosis and mitigates DMCM, we
treated db/db mice with the H₂S slow-releasing donor GYY4137. This study establishes
ferroptosis as a new, non-apoptotic form of

Figure 3.2: Research Goal III Hypothesis. H2S prevents DMCM in part by
preventing ferroptosis.

cell death in DMCM and H₂S as a novel regulator of cardiac ferroptosis. It also unfolds the therapeutic potential of H₂S in mitigating
DMCM by suppressing myocardial cell death via ferroptosis.
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METHODS – III
Animals and H₂S Donor Treatment
LepRdb/db mice and their sibling control LepRdb/+ on the C57BL/6J background (The
Jackson Laboratory) were procured and bred at the University of Nebraska Medical Center.
All animal studies were performed following the National Institutes of Health guidelines
and protocol approved by the Institutional Animal Care and Use Committee (IACUC) of
the University of Nebraska Medical Center. The experimental plan for the mice is shown
in Figure 3.3.
Only mice with hyperglycemia at 6 weeks were enrolled in the study for treatment
and later ferroptosis measurement. We enrolled mice randomly on a rolling basis, and
additional mice to account for non-responders until n=8 (pre-determined by power analysis
below) was reached. Care of mice followed guidelines for reproducibility in diabetes models.(71) Extra food was provided at the bottom of the cage for obese mice, which cannot
reach food easily. Stress, which can delay diabetic phenotypes, was prevented by providing extra enrichment. Fasting blood glucose and body weight, was measured weekly after
6 hours of fasting by an Accu-Chek Aviva glucometer (Roche, USA). Measurements were
taken at the same time of day and same location (tail vein capillary blood draw) to minimize
variability.
8-week old db/+ and db/db mice will be randomly chosen for treatment with the
H₂S slow releasing donor GYY4137 (cat # 13345, Cayman Chemical). 50 mg/kg
GYY4137 in 5% DMSO in saline will be injected by IP administration for 12 weeks daily at
the same time of day to minimize circadian effects. Control groups were injected with 5%
DMSO in saline (Veh).
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Figure 3.3: Schematic of in vivo and in vitro studies. A: db/db mice, with mutated
leptin receptor (Leprdb) and their littermate controls were treated with the H₂S donor
GYY4137 for daily 12 weeks by I.P. injection or 5% DMSO in saline as vehicle control
(Veh). Physiological and molecular analysis of the left ventricle was performed at 20
weeks of age. B: In vitro studies were performed in neonatal cardiomyocytes isolated
from 1 to 3-day-old C57BL/6J mice (same background as db/db mice). Cells underwent
pharmacological treatment with ferrostatin-1, a ferroptosis inhibitor and RSL3, a ferroptosis inducer.
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Determining ferroptosis in vivo db/db hearts
Ferroptosis will be measured in hearts of db/db mice and their non-diabetic db/+
controls at the end of the in vivo experiment. GPX4 and lipid peroxidation markers are
highly specific to ferroptosis.(119) GPX4 activity was measured in LV tissue lysate by an
enzymatic assay, 4-HNE lipid peroxide (oxidized fatty acid which forms membrane adducts) by ELISA (ab102530, ab238538, Abcam), and GPX4 expression by Western blotting from LV tissue. These measurements occurred on the same day hearts are removed
from the animals, and lysis buffer without SDS was used for protein isolation to preserve
GPX4 activity (supplied with GPX4 assay). Malondialdehyde (MDA), a lipid peroxide
PUFA breakdown product, was measured concurrently in LV tissue by an MDA assay kit
(MAK085, Sigma).
Evaluation of Cardiac Function (Echocardiography AND PV LOOP RECORDING)
At the end of the treatment regimen, cardiac function was assed in all mice as
previously described (Chapter 1: Evaluating Cardiac Function with Pressure-Volume Recording). After recording baseline hemodynamics, the inferior vena cava was briefly occluded to determine load-dependent measures such as end-diastolic pressure-volume relationship (EDPVR), which gives a more sensitive measurement of diastolic function.
These methods follow the recommended guidelines for measuring in vivo cardiac function.(101)
Echocardiography was performed at the end of the experiment to determine stroke
volume for each mouse (Vevo 3100, Visual Sonics) at the UNMC Small Animal Ultrasound
Core. Heart rate was maintained at ~450 bpm by titrating anesthesia. The mean stroke
volume for each group of animals was used to calibrate the volumes determined by the
PV loop catheter using (AdVol, Transonic).
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Evaluation of Cardiac Remodeling
After in vivo treatments, hearts were removed and weighed for gravimetric hypertrophy measurement (heart weight/tibia length). Hearts were then flash-frozen for sectioning (or downstream protein analysis). Hearts were stained for collagen to assess fibrosis
and H&E to assess cardiac hypertrophy as described in Chapter 1: Histological Analysis. Molecular markers of fibrosis (increased TGF-β), hypertrophy (increased β-myosin
heavy chain) were measured in the left ventricle by Western blotting.
In Vitro Inhibition and Induction of Ferroptosis
The effect of hyperglycemia to induce ferroptosis, specifically in cardiomyocytes,
was assessed by pharmacological inhibition of ferroptosis signaling in cultured cardiomyocytes. Neonatal cardiomyocytes were isolated from 1 to 3-day-old C57BL/6J mice (Cardiomyocyte isolation kit, Thermo) with inhibition of fibroblast contamination. Cells were
counted (TC20 cell counter, BioRad) before plating on fibronectin-coated plates to ensure
consistent cell death measurement. 7 days after isolation and plating of cells, the cardiomyocytes were cultured for 24 hours in complete cardiomyocyte media supplied with the
isolation kit or high glucose fortified media (25 mM). To balance osmolality, we added
25 mM of mannitol to normal media.
Ferrostatin-1 is a highly specific ferroptosis inhibitor that does not have off-target
effects.(207) Cells were treated with treated with ferrostatin-1 (100 uM in 5% DMSO in
PBS) or 5% DMSO in PBS control for 24 hours (from 6 weeks of age when most db/db
mice demonstrate hyperglycemia to the end of the experiment at 14 weeks). Cells were
lysed with SDS free lysis buffer or used for immunofluorescence staining to determine the
effect of ferroptosis inhibition on lipid peroxide formation and cell death in hyperglycemia.
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Induction of Ferroptosis
To validate the anti-ferroptotic potential of H₂S, we pharmacologically induced ferroptosis in neonatal cardiomyocytes with RSL3 and treated them with GYY4137. After
cells are established 7 days after isolation, they were treated with 1 ug/ml RSL3 in PBS,
which directly inhibits GPX4 to induce ferroptosis, and 100 μM GYY4137 for 24 hours.
GPX4 activity, 4-HNE, and cell death were measured to confirm the induction of ferroptosis and effect of GYY4137.
Immunocytochemistry
Cultured cells were stained for oxidative stress and 4-HNE lipid peroxide after
ferroptosis induction or inhibition and H₂S donor treatment. 10,000 neonatal cardiomyocyte cells were seeded onto a fibronectin-coated 24 well plate or chamber slides
(354118, ThermoFisher). After 24 h, cells were fixed with 10% formalin for 20 min and
then washed them with ice-cold phosphate buffered saline (PBS) three times with 5 min
intervals. For permeabilization, we incubated cells in 0.1% triton X-100 for 10 min and
then washed them with ice-cold PBS three times with 5 min intervals. Cells were then incubated with 4-HNE primary antibody (1:100, ab48506, Abcam) overnight at 4 °C or
CellROX stain (C10444, ThermoFisher) following the manufacturer protocol. After washing the cells with ice-cold PBS three times with 5 min intervals, they were incubated with
fluorescence-tagged secondary antibody for 1 h at RT and counterstained with 1 µg/ml
DAPI for 3–5 min, washed one time with PBS, and observed under an EVOS microscope or a Leica TCS SPE confocal microscope with an oil immersion objective of 60x.
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In vitro Measurement of Cell Death
Total cell death in hypergylcemia cultured cardiomyocytes was assessed by cell
toxicity. Lactate dehydrogenase (LDH) release was be measured to correlate with dying
cells before and after GYY4137 treatment (LDH-Glo Assay, Promega).
RESULTS – III
Db/db Mice Exhibit Obesity, Hyperglycemia, and Cardiac Hypertrophy
We assessed fasting blood glucose and gravimetric characteristics in male and
female db/db mice along with their heterozygous sibling controls at the end of the study at
20 weeks of age (Table 3.1: Gravimetric and glucose parameters in db/db mice
treated with GYY4137Table 3.1). Vehicle treated db/db mice demonstrated elevated
body weight compared to control mice consistent with the db mutation in LepR. Heart
weight (HW) and HW normalized to tibia length (TL) were elevated in db/db mice, indicating cardiac hypertrophy. Kidney weight also was elevated in db/db mice. Fasting glucose
was elevated at the 20 week age. This data demonstrating hyperglycemia and cardiac
hypertrophy combined with the evidence of cardiac remodeling and cardiac dysfunction
presented below confirmed the presence of DMCM in db/db mice consistent with the
guidelines for models of DMCM.(28)
GYY4137 H₂S donor treatment in db/db mice did not reduce body weight, heart
weight/ tibia length, or fasting blood glucose.
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Table 3.1: Gravimetric and glucose parameters in db/db mice treated with
GYY4137
Parameter

db/+ +
(n=7)

Body Weight
(g)

veh

db/db + veh
(n=7)

db/db
GYY4137
(n=7)

26.2±1.2

51.9±1.0*

52.8±1.4

29.3±5.0

Heart Weight
(HW) (mg)

114.7±4.9

136.5±5.7*

129.6±1.8*

117.9±12.6

HW/TL
(mg/mm)

6.6±0.2

8.3±0.3*

7.6±0.1*

5.7±0.4

Kidney
Weight (mg)

150.0±3.8

203.3±9.3*

191.7±2.9*

169.0±12.2

Fasting Glucose (mg/dL)

137.0±10.5

196.6±12.5*

171.0±15.2*

132.0±13.2

*P<0.05 vs. db/+ + veh

+

db/+
GYY4137
(n=7)

+
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H₂S Prevents Elevated Ferroptosis in DMCM
We measured several markers of the ferroptosis cell death signaling pathway in
the LV of 20 week old db/db mice in accordance with guidelines for measuring cardiac
ferroptosis (Figure 3.4). GPX4, the negative regulator of ferroptosis, showed decreased
protein expression and enzymatic activity in the LV of db/db + veh mice (Figure 3.4A-B).
In addition, the lipid peroxide inducers of ferroptotic cell death, 4-HNE and MDA, were
increased in concentration in the db/db + veh heart (Figure 3.4C-D). Together, these
findings are consistent with an increase in in vivo ferroptosis signaling in DMCM.
GYY4137 H₂S donor treatment prevented the in vivo elevation of ferroptosis. GPX4 expression or activity were normalized to near control levels in db/db + GYY4137 mice.
Similarly 4-HNE and MDA lipid peroxides were reduced in the db/db + GYY4137 LV
compared to db/db + veh LV.
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Figure 3.4: Elevated markers of ferroptosis in the DMCM heart are mitigated by
H₂S donor treatment. A-B: Glutathione peroxidase 4 (GPX4), which inhibits ferroptosis,
expression (A) and activity (B) are reduced in DMCM and elevated after GYY4137 H₂S
donor treatment. C-D. 4-HNE and MDA lipid peroxide products which induce ferroptosis
were elevated in DMCM which were reduced by GYY4137. All bars expressed as
mean±SEM with dots representing each animal. One-way ANOVA was used for statistical analysis.
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Hyperglycemia Induces Ferroptosis in Cardiomyocytes
We measured ferroptosis markers and cell death in neonatal cardiomyocytes in a
hyperglycemic microenvironment to support the in vivo findings. Cardiomyocytes incubated in high glucose (HG) exhibited increased 4-HNE lipid peroxide assessed by immunocytochemistry and ELISA (Figure 3.5A-B). GPX4 activity was also reduced in HG
treated cardiomyocytes. The inhibitor of ferroptosis signaling, ferrostatin-1, significantly
reduced 4-HNE and increased GPX4 activity demonstrating HG induces ferroptosis specifically.
To determine if H₂S can also inhibit ferroptosis in cardiomyocytes, we treated HG
treated cardiomyocytes with GYY4137. The H₂S donor treatment prevented the increase
in 4-HNE lipid peroxide in the HG environment (Figure 3.5C). Finally, to determine if the
alterations in ferroptosis signaling lead to alterations in cardiomyocytes' cell death, we
measured LDH, which is released after cell death, after treatment conditions (Figure
3.5D). HG treatment increased cell death in neonatal cardiomyocytes, similar to the increase in 4-HNE. GYY4137 treatment in HG reduced LDH consistent with the decrease
in ferroptosis.
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Figure 3.5: Elevated ferroptosis and cell death in hyperglycemia are inhibited by
ferrostatin-1 and H₂S in cardiomyocytes. A: 4-HNE staining in neonatal cardiomyocytes cultured in hyperglycemia (HG) shows an increase in cytosolic expression of 4HNE lipid peroxides in HG. The ferroptosis inhibitor ferrostatin (FS) prevented formation
of 4-HNE in HG. B: GPX4 activity was reduced and 4-HNE was increased in HG treated
cardiomyocytes indicating activation of ferroptosis. FS normalized GPX4 activity and 4HNE. C: GYY4137 H₂S donor also prevented the increase in 4-HNE lipid peroxide in HG
treated cardiomyocytes. D: Hyperglycemia increased cell death measured by release of
lactate dehydrogenase from neonatal cardiomyocytes which was prevent by GYY4137
treatment. All bars expressed as mean±SEM with dots representing biological cell culture replicates. One-way ANOVA was used for statistical analysis.
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H₂S inhibits Ferroptosis in Cardiomyocytes
To validate the anti-ferroptotic potential of H₂S seen in vivo in DMCM and in HG
treated cardiomyocytes, we treated cardiomyocytes with H₂S after direct pharmacological induction of ferroptosis with RSL3. RSL3 covalently inhibits GPX4 to induce ferroptosis directly. RSL3 in neonatal cardiomyocytes increased cytosolic reactive oxygen species (ROS) visualized by CellRox stain consistent with an inhibition of GPX4 (Figure 3.6
A). As expected, RSL3 treatment increased cellular 4-HNE, indicating increased ferroptosis (Figure 3.6B). GYY4137 treatment concurrent with RSL3 treatment prevented the
increase in ROS and an increase in 4-HNE.
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Figure 3.6: Pharmacologic induction of ferroptosis in cardiomyocytes is inhibited
by GYY4137. A: RSL3 treatment, which inhibits the antioxidant GPX4 to induce ferroptosis, increases ROS in neonatal cardiomyocytes which was be inhibited by GYY4137 pretreatment. Scale bar = 200 uM. B: RSL3 treatment increased 4-HNE lipid peroxide
staining in neonatal cardiomyocytes which was prevented by both GYY4137 and ferrostatin. Scale bar = 5 uM.
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H₂S inhibits Cardiac Remodeling in DMCM
Since prevention in cardiac ferroptosis and cell death by H₂S would also prevent
DMCM induced cardiac remodeling, we evaluated cardiac fibrosis, and cardiac hypertrophy in GYY4137 treated db/db mice. db/db + Veh mice exhibited increased collagen in
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the LV in an interstitial fibrosis pattern

(
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Figure 3.7A). TGF-B1, a molecular marker and signaling activator of fibrosis,
also was increased in the LV in its activated form

(
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Figure 3.7B). GYY4137 treated db/db mice showed reduced interstitial fibrosis
and reduced TGF-B1 expression. GYY4137 treatment showed no effect in control db/+
mice.
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Figure 3.7: Cardiac fibrosis in DMCM is prevented by H₂S donor treatment. A: Sirius red collagen staining indicating interstitial fibrosis was elevated in the db/db left ventricle in addition to activated TGF-B fibrosis signaling marker expression (B) which were
both reduced by GYY4137. Two similar areas of the left ventricle (boxes) were analyzed
in each animal and fibrosis was quantified by calculating % area red per uniform area.
Scale bar = 200 μm. All bars expressed as mean±SEM with dots representing each animal. One-way ANOVA was used for statistical analysis.
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Cardiac hypertrophy was evaluated by measuring cardiomyocyte size stained
with H&E in the same area of the LV in all mice groups (Figure 3.8). db/db mice demonstrated increased cardiomyocyte size (fewer cells per uniform area) and increased
HW/TL (Table 3.1), indicating hypertrophy of the heart. The fetal myosin isoform BMHC, which increases during pathological remodeling, showed increased expression in
the db/db heart. GYY4137 in db/db mice reduced cardiomyocyte size (more cells/ uniform area) and reduced B-MHC expression though it did not normalize HW/TL.
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Figure 3.8: Cardiac hypertrophy in DMCM is prevented by H₂S donor treatment. A:
H&E staining to measure cardiomyocyte size shows larger cardiomyocytes in the DMCM
left ventricle, indicating hypertrophy. Cardiomyocyte size was reduced with GYY4137
treatment. Two similar areas of the left ventricle (boxes) were analyzed in each animal
and size was quantified by counting cells per uniform area. B: The elevation of B-Myosin
Heavy Chain in the db/db heart, a marker of fetal re-programming and hypertrophy was
also reduced by GYY4137. Scale bar = 30 μm. All bars expressed as mean±SEM with
dots representing each animal. One-way ANOVA was used for statistical analysis.
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H₂S Prevents Cardiac Dysfunction in DMCM
Diastolic and systolic function were evaluated in vivo with hemodynamics recoding of PV loops at the end of the experiment. The 20-week old db/db mice had similar
end-diastolic volumes (EDV) to control mice but a right-ward shift in end-systolic volume
(ESV) indicating impaired systolic function (Figure 3.9). Mean baseline hemodynamic
parameters such as a decrease in stroke volume and cardiac output further support a
decrease in systolic function. Furthermore, the relaxation rate constant Tau was elevated in db/db mice indicating impaired diastolic function. GYY4137 treatment normalized ESV, stroke volume, and cardiac output in db/db mice but did not restore Tau. Ejection fraction was not statistically altered between groups.
We also evaluated load-dependent cardiac function measures varying preload by
occlusion of the inferior vena cava (Figure 3.10). The end-diastolic pressure volume relationship (EDPVR) slope was increased in db/db mice, indicating a stiffer, less compliant heart. GYY4137 normalized EDPVR indicating a restoration of one measure of diastolic function. Other load-dependent measures were unchanged between groups.
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Figure 3.9: GYY4137 treatment improved left-ventricle cardiac dysfunction in
db/db mice. A: Representative LV pressure volume loop hemodynamics show an increase in end systolic volume signifying an impairment of systolic function in the left ventricle of db/db mice. B: GYY4137 treatment in db/db mice normalized end systolic volume and stroke volume. Averaged baseline hemodynamics of stroke volume (C), cardiac output (D), ejection fraction (E), dp/dt min (F), and Tau relaxation constant (G). Average heart rate was unchanged across groups (H). All bars expressed as mean±SEM
with dots representing each animal. One-way ANOVA was used for statistical analysis.
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Figure 3.10: GYY4137 treatment improved load-independent left-ventricle cardiac
dysfunction in db/db mice. A-D: Representative occlusion LV pressure volume loop
hemodynamics indicating the slope of the end diastolic pressure volume relationship
(EDPVR) measure of LV compliance. E: GYY4137 treatment in db/db mice normalized
EDPVR. End systolic pressure volume relationship (F, ESPVR) and pressure recruitable
stroke work (G, PRSW) were unchanged. All bars expressed as mean±SEM with dots
representing each animal. One-way ANOVA was used for statistical analysis.
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Figure 3.11: Working model for the inhibition of ferroptosis signaling and cell
death in the DM heart by GYY4137 to improve cardiac function. H₂S donor
GYY4137 prevented the increase and ferroptotic signaling and cell death in the db/db
mouse LV. GYY4137 also prevented cardiac remodeling and cardiac dysfunction, a consequence of cardiomyocyte cell death.
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SUMMARY OF RESULTS – III
Despite clinical evidence of the role of lipotoxicity and iron overload in the diabetic
heart, of the six major forms of cell death identified in the heart, only the regulation of
ferroptosis is unknown in the DM heart. In this study, we demonstrate an increase in in
vivo ferroptosis signaling in the DM heart of db/db mice. H₂S donor treatment inhibited in
vivo ferroptosis signaling Figure 3.11. Further, we demonstrate in vitro that hyperglycemia
increases ferroptosis markers and cell death in cardiomyocytes which can be ablated by
both a pharmacologic inhibitor of ferroptosis and H₂S donor treatment. In vitro direct induction of ferroptosis with RSL3 was inhibited by H₂S, confirming the anti-ferroptotic effects of H₂S.
DISCUSSION – III
At 20 weeks of age, db/db mice showed all the criteria for small animal models of
DMCM.(28) This includes diabetes, evidence of cardiac fibrosis and hypertrophy and cardiac dysfunction. There are conflicting reports on the presence of systolic dysfunction in
db/db mice before 14 weeks of age (animal models). At 20 weeks of age, db/db mice
showed clear signs of systolic dysfunction and some signs of diastolic dysfunction. H₂S
donor treatment with GYY4137 did not reduce blood glucose but prevented all signs of
DMCM, including preventing fibrosis, hypertrophy, and systolic dysfunction. Since in vivo
data showing H₂S prevents DMCM, this study adds strong evidence that H₂S based therapies may have therapeutic potential in DMCM.
An inhibition of diabetes-induced cardiac ferroptosis accompanied the improvement in cardiac structure and function by GYY4137. Our studies do not exclude other
forms of cell death occurring in the DM heart and do not suggest H₂S is inhibiting only
cardiac ferroptosis. In fact, growing evidence suggests H₂S inhibits multiple forms of cell
death in DMCM.(73) While H₂S does not seem to be regulating hyperglycemia that causes
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cardiomyocyte cell death since blood glucose was not altered in db/db mice with GYY4137,
H₂S could be regulating upstream signaling that inhibits ferroptosis and other forms of cell
death.
First, our data suggest H₂S protects against ferroptosis by increasing GPX4 activity. In neurons, the addition of H₂S increases GSH levels by directly stimulating GSH production and increasing intracellular cysteine by increasing its transport into the cell via the
cysteine/glutamate antiporter (system Xc- or xCT).(56, 83) H₂S also increases mitochondrial GSH,(83) which could reduce mitochondrial-derived ROS that oxidizes lipids. Increased GSH via H₂S should increase GPX4 activity to inhibit lipid peroxidation.
We also observed an upregulation of GPX4 gene expression with GYY4137
treatment. GPX4 is transcriptionally regulated by the transcription factor nuclear factorE2-related factor (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1). Therefore,
Nrf2 is a is a key inhibitor of ferroptosis by inducing the expression of antioxidant response elements. Numerous publications show that change in Nrf2 expression or function alters the progression of DMCM (26, 95, 183). New evidence links H₂S signaling to
Nrf2-mediated cell death. Two studies have shown that incubation of mouse fibroblasts
with a H₂S donor directly sulfhydrated Keap1, which enhanced Nrf2 translocation and increased expression of antioxidant genes (61, 196). This protected against age-related
cellular senescence and induced cytoprotective genes. While the effect of H₂S sulfhydration of Keap1 on ferroptosis is yet to be explored, the cardioprotective effects of H₂S in
cardiomyopathy may be mediated by this pathway.
Finally, alterations in lipid handling in DMCM may cause an increase in PUFA peroxidation. Lipids are oxidized by lipoxygenases (LOX) such as 15-LOX, which leads to
ferroptotic membrane damage. LOXs are thus pro-ferroptotic, and diabetic retinas and
hearts show increased 15 and 5-LOX expression.(52) In addition, solute carriers (SLCs)
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have been implicated in the regulation of the PUFA lipid synthesis and ferroptosis.(6, 31)
H₂S and gasotransmitters may regulate SLC activity by modifying cysteine residues on
these proteins.(144)
Because of these signaling effects of H₂S upstream of the production of ROS, H₂S
may act as a better therapeutic agent in DMCM. Vitamin E, which should increase GSH
and reduce ferroptosis, failed to reduce cardiovascular disease in diabetic patients.(50,
103) This study and others suggest H₂S is a signaling molecule with effects besides being
a direct antioxidant including regulating transcription factors and sulfhydrating proteins(2,
150) – which could be more efficacious in halting DMCM.
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CHAPTER 4: EXERCISE TRAINING PROMOTES CARDIAC HYDROGEN SULFIDE
BIOSYNTHESIS AND MITIGATES PYROPTOSIS IN DIABETIC CARDIOMYOPATHY
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INTRODUCTION – IV
Obesity, primarily due to changes in diet to higher fat and higher sugar foods, independently increases the risk of developing heart failure.(66) Metabolic syndrome from
obesity leads to type 2 diabetes (T2DM) that progresses to diastolic dysfunction and diabetic cardiomyopathy (DMCM).(1, 41, 179) In rodents however, high-fat diet (HFD) models
have produced inconclusive effects on cardiac dysfunction and remodeling, and thus the
molecular mechanisms by which HFD leads to DMCM are not well-established.(5, 21, 40)
Alternatively, human and rodent studies show exercise training (EX) regimens improve cardiac function in metabolic syndrome and diabetes. EX reduces mortality in diabetic patients and increases cardiac output and contractility.(98, 188) EX was found to
normalize diastolic function in HFD-fed obese and T2DM mice.(36, 105) Therefore, a better understanding of the molecular mechanisms induced by EX to ameliorate cardiac dysfunction would lead to novel therapeutic targets for DMCM – especially in patients unable
to exercise.
Cardiomyocyte cell death is a key molecular event in the progression of DMCM, as
the death of terminally differentiated cardiomyocytes leads to loss of contractile units and
instigates fibrosis.(17) In metabolic syndrome, the diabetic environment of hyperglycemia,
inflammatory cytokines, oxidative damage, and lipotoxicity induces several types of cell
death, including non-inflammatory (apoptosis), and inflammatory (pyroptosis) cell death in
the heart.(93, 107, 173) Pyroptosis is an inflammasome-mediated cell death mechanism
where activation of the NOD-like receptor protein 3 (NLRP3) inflammasome activates
caspase-1 and results in cell lysis and release of IL-1β.(12) Hyperglycemia, fatty acids,
and oxidative stress activate NLRP3 and caspase-1-mediated inflammasome, and inhibition of NLRP3 mitigates DMCM in diabetic rats.(106, 156, 177) Furthermore, HFD and
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obesity lead to inflammasome activation and infiltration of macrophages into adipose tissue, the key player in pyroptosis.(51, 177) However, the role of pyroptosis in obesity-induced cardiac remodeling is unclear. Vandanmagsar et al. demonstrated that EX reduces
pyroptotic cell death in adipose and liver tissue, however, this effect has not been evaluated in the heart.(177)
Hydrogen sulfide (H₂S), a cardioprotective gaseous signaling molecule produced by
homocysteine transsulfuration, prevents adverse cardiac remodeling and cell death,
including pyroptosis.(73) H₂S inhibits caspase-1 activity and IL-1β secretion both in vitro
and mouse model of inflammation.(23) It also suppress several markers of pyroptosis in
an ischemia cardiomyopathy model.(172) Notably EX may restore bioavailability of H₂S
in hepatocytes of HFD-fed mice (180). However, it is unknown whether H₂S is an
underlying mechanism of cardioprotection via EX.
Hypothesis and Aims
In this study, we aimed to determine whether a HFD leads to DMCM in mice, the
molecular mechanisms by which HFD leads to cardiomyopathy, and the mechanisms by
which EX can mitigate HFD-induced cardiomyopathy. We tested the hypothesis that HFDmediated obesity induces DMCM by increasing pyroptosis, and structural and metabolic
remodeling, which are prevented by EX via increased biosynthesis of H₂S.
METHODS – IV
Animal Models and Treatment
Ten-week-old male C57BL/6J mice (The Jackson Laboratory) were randomly separated into four treatment groups: 1) normal diet (ND), 2) ND mice performing exercise
training (NDEX), 3) HFD, and 4) HFD performing EX (HFDEX). The normal diet contained
17% kcal from fat and 3.1 kcal/g total (Teklad Diet 7012, Envigo). The HFD contained 45%
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kcal from fat and 4.7 kcal/g total (Teklad Diet 08811, Envigo). Mice were treated with the
different diets and exercise regimens for 20 weeks (Figure 4.1).
Mice were maintained in the animal facility of the University of Nebraska Medical Center with a twelve-hour light/dark cycle and provided with food and water ad-libitum. The
amount of food consumed by each cage was measured on a bi-weekly basis and divided
by the number of animals in the cage to estimate food intake for each mouse. Body weight
of each mouse was measured weekly.
All animal studies were performed following the guidelines of the National Institutes
of Health and the protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center.
Exercise training (EX) regimen
Mice in EX groups underwent moderate-intensity treadmill exercise and were pretrained for four days before the experiment regimen. The speed and duration of the treadmill run was gradually increased to adapt to the final speed with zero degrees incline. Mice
ran on the treadmill five days/week for twenty weeks, except on the days when glucose or
insulin tolerance tests were conducted. The sedentary mice were also brought to the
treadmill with the EX mice, but they were kept away from the running belt. Therefore, the
sedentary mice experienced the stress of handling, noise, vibrations, and lack of food and
water during the exercise training period that EX mice experienced except the actual running on the treadmill.
Dual Energy X-Ray Absorbance
Dual Energy X-Ray Absorptiometry (DEXA, Lunar Piximus, GE) was performed during the week 18 to measure differences in body composition. Prior to scanning, calibration
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was performed using the calibration phantom provided by the supplier. Mice were anesthetized with isoflurane during scanning. The DEXA system uses a cone beam X-ray
source generating energies of 35 and 80keV and a flat detector having individual pixel
dimension of 0.18 x 0.18 mm.
Glucose and Insulin Tolerance Tests (GTT, ITT)
We performed intraperitoneal GTT after 14 and 18 weeks of treatment. Mice were
fasted for seven hours prior to an intraperitoneal glucose injection (2g glucose/kg body
weight in a 20% solution in saline). Blood glucose was measured before the injection and
at different time intervals (15, 30, 45, 60, 90, and 120 minutes) following injection by an
Accu-Chek Aviva glucometer (Roche, USA).
Intraperitoneal ITT was assessed at the same time points on different days than the
GTT. An intraperitoneal injection of 0.75 U insulin /kg body weight (Humulin R, Lilly, USA)
was given to the mice fasted for seven hours. Blood glucose levels were measured before
and after insulin injection at the time intervals of 15, 30, 45, 60, and 90 minutes.
Left Ventricle Hemodynamics
Pressure-volume loop recordings were performed in the left ventricle at the end of the
20-week diet and exercise training regimen by using an open chest procedure as described previously.(77) A 4mm 1.2F catheter probe (Transonic) was inserted into the left
ventricle via the heart apex and volume measurements were calibrated automatically by
admittance from the probe. Measurements were made following the best practice guidelines for invasive hemodynamic measurement in mice.(101) Heart rate was maintained at
450 to 500 bpm by adjusting anesthesia (1-2% isoflurane) and maintaining body temperature at 37 ℃. Baseline load dependent pressure-volume recordings were made after confirming the placement of the catheter in the left ventricle. Hemodynamic parameters of
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diastolic and systolic function were derived by averaging at least 20 cardiac cycles from
the recordings using the LabChart Pro PV Loop Analysis Add-On.
Western blotting
The left ventricle of mouse hearts previously frozen at -80 °C were homogenized with
a glass homogenizer using RIPA buffer (BP-115, Boston BioProducts) with protease and
phosphatase inhibitor (MSSAFE, Sigma). 25-30 ug of protein were loaded onto SDS
PAGE gels. Membranes were blocked with 5% milk for at least 30 min, incubated with
primary antibody overnight at 4 °C and secondary antibody for 2 hours at room temperature. Band intensity was determined using Bio-Rad Image Lab software. Protein expression was normalized against total protein measured by Ponceau staining, as cardiac remodeling may alter housekeeping protein expression.(15)
The primary antibodies used were: IL-1β (1:1000, 52718S, Cell Signaling), Caspase1 (1:1000, ab1872, Abcam), NLRP3 (1:1000, NBP2-12446, Novus), ASC (1:100, sc54414, Santa Cruz), β-MHC (1:1000, ab172967, Abcam), CSE (1:1500, H00001491-M02,
Abnova), CBS (1:1000, H00000875-M01, Abnova), Homocysteine (1:1000, ab15154,
Abcam), 3-mercaptopyruvate sulfurtransferase (MPST, 1:100, ab85377, Abcam), SP-1
(1:1000, 07-645, Millipore), phospho-SP-1 (1:1000, ab59257, Abcam), BiP (1:1000, 3177,
Cell Signaling), CHOP (1:1000, ab141019, Abcam), GLUT4 (1:2500, ab654, Abcam) and
TGF-β1 (1:100, sc146, Santa Cruz). The secondary antibodies used were anti-mouse
IgG-HRP, and anti-rabbit IgG-HRP (used at half the concentration of the respective primary antibody dilution, Cell Signaling).
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Gene Expression Assays
RNA was isolated from the left ventricle using the mirVana isolation kit (AM1560,
Thermo Fisher) for both total and small RNA. For mRNA quantification, cDNA was synthesized with iScript cDNA synthesis (Bio-Rad) and amplified using SYBR green in a CFX
qPCR instrument (Bio-Rad). We used 18s rRNA as an endogenous control. The primer
sequences were: 18s (NR_003278), forward 5′GTAGTTCCGACCATAAACGA3′ and reverse 5′TCAATCTGTCAATCCTGTCC3′, and CBS (NM_144855) forward 5′TGCGGAACTACATGTCCAAG3′ and reverse- 5′TTGCAGACTTCGTCTGATGG3′.
cDNA for miRNA was synthesized using the TaqMan® microRNA reverse transcription
kit (Life Technologies, USA, catalog # 4366597). cDNA was amplified with TaqMan primers for miR-133a, miR-29b, and miR-30a and the endogenous control U6 snRNA
(Thermo Fisher) Gene expression was quantified using CFX Manager 3.0 software (BioRad).
Histology and Electron Microscopy
5 µm transverse paraffin heart sections were used for picrosirius red staining, which
stains collagen in red. Staining was performed by the UNMC Tissue Sciences Core Facility. A VWR bright-field microscope was used for imaging slides. The same area of the left
ventricle was imaged for each heart. Transmission electron microscopy of sections of the
left ventricle fixed with EM grade Trump’s fixative was performed with a Tecnai G2 Spirit
transmission electron microscope (FEI Company).
Hydrogen sulfide measurement
H₂S was measured in serum and tissue using gas chromatography as previously
described.(136) Previously frozen blood or homogenized tissue was incubated with 1 M
sodium citrate buffer at 37 °C with shaking to release H₂S before gas chromatography
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analysis. Concentrations of H₂S were calculated against a standard curve of Na2S, and
tissue concentrations were normalized against mg of protein added to the buffer using
BCA protein measurement.
Statistical analyses
To compare the means from four groups, we used one-way analysis of variance
(ANOVA), followed by Tukey’s post-hoc test, using GraphPad Prism 8.0. Repeated
measures of ANOVA were used when the same measurements were taken multiple times
on an animal over time. Samples and data analysis were blinded or performed by different
analysts wherever possible. Sample sizes (8 animals/group) were determined by power
calculation prior to commencement of the study based on variability of historical data.
RESULTS – IV
High-fat diet induces obesity and T2DM phenotype in mice
To validate HFD-induced obesity in mice, body weight and body fat were monitored
during the treatment regimens. Mice started at the same average body weight across all
groups. HFD caused a rapid increase in body weight within eight weeks when compared
to the mice on a normal diet (ND) (Figure 4.1). At the end of the 20-week diet regimen,
HFD-fed mice gained an average of 15.6 grams from the start of the regimen when compared to ND-fed mice, which only gained an average of 4.33 grams. This corresponded to
the increased body fat percent in HFD mice when measured with DEXA (Figure 4.1). After
18 weeks of HFD feeding, mice had an average body fat percentage of 32.7±1.94% when
compared to their ND-fed littermates, which had 18.5±1.65% body fat. DEXA imaging
demonstrated that the increase in body fat occurred primarily in the abdominal area, confirming visceral obesity.
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Figure 4.1: Exercise training prevents high-fat diet-induced obesity in mice. A.
Timeline for diet and exercise training plan. Mice were randomly chosen for 20 weeks of
high-fat diet (HFD) and exercise training (EX) at 10 weeks of age. All timepoints are reported as weeks of treatment starting at 10 weeks of age. B. Average weekly body
weight in the four groups of mice: normal diet (ND), HFD, HFD mice on exercise training
(HFDEX), and ND mice on exercise training (NDEX). N=8/group. C. Food consumption
over a two-week period was unchanged between groups. D. Total calorie intake was increased in HFD treated mice. E. Representative DEXA imaging of mice after 18 weeks
of diet and exercise training regimen. F. Quantification of % body fat from DEXA. HFD
treatment increased % body fat, which was prevented by exercise training. All values expressed as mean±SEM with dots representing each animal. One-way ANOVA and
Tukey’s post-hoc test was used for statistical analysis. Repeated measures of ANOVA
were used for B. *P<0.05 between ND and HFD. Previously published in (75).
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Exercise training during HFD feeding slightly reduced body weight in HFD mice, which
was not statistically significant. However, exercise training reduced % body fat in HFD
mice (20.4% reduction). Average grams of food consumed over 2 weeks was the same
across all groups of mice (Figure 4.1C), suggesting that weight gain was due to the increased fat content of the diet itself and not increased consumption.
The HFD-induced obesity in mice led to features of T2DM. Fasting baseline blood
glucose was elevated in HFD mice (Table 4.1). Impaired glucose tolerance was observed
in obese mice after 14 weeks of the diet regimen during glucose tolerance tests (GTT).
Plasma glucose concentrations were elevated from 30 min to 120 min after glucose injection in HFD mice when compared to ND mice (Figure 4.2A & B). Insulin sensitivity was
also impaired with HFD at 14 weeks as HFD mice demonstrated elevated glucose for 90
min after injection of insulin (Figure 4.2C & D). Glucose intolerance remains similar after
18 weeks of HFD regimen. Exercise led to improvements in glucose handling. Fasting
glucose was reduced in HFD mice with exercise, glucose tolerance was improved at 14
weeks, and insulin sensitivity showed a trend toward improvement (Figure 4.2A-D).
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Figure 4.2: Exercise training prevents HFD-induced development of T2DM phenotype. A, B. Intraperitoneal glucose tolerance test (GTT) at 14-week treatment in the four
groups of mice: normal diet (ND), high-fat diet (HFD), HFD mice on exercise training
(HFDEX) and ND mice on exercise training (NDEX). Blood glucose was measured for 2
hours at several time points after the injection of glucose. Glucose clearance was decreased in HFD but improved with EX. N=8. C, D. Intraperitoneal insulin tolerance test
(ITT) at 14-week treatment. Blood glucose concentrations were measured for 1.5 hours
after the injection of insulin. Insulin resistance was higher in HFD as compared to ND
group. *, P<0.05 between ND and HFD. #, P<0.05 between HFDEX and HFD. All values
are expressed as mean±SEM with dots representing each animal. One-way ANOVA and
Tukey’s post-hoc test was used for statistical analysis. Previously published in (75).
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Table 4.1: Gravimetric characteristics of mice with 20 weeks of normal and highfat diet with or without exercise training.
ND

HFD

HFDEX

NDEX

(n=8)

(n=8)

(n=8)

(n=8)

Body Weight (g)

26.7±0.57

35.6±2.13*

35.2±1.04*

27.2±0.43

Heart Weight (mg)

124±5.92

137±6.82

146±7.01

125±3.43

HW/TL (mg/mm)

6.87±0.35

7.81±0.31

8.23±0.38

7.08±0.18

Fasting Glucose (mg/dL)

162±9.13

213±13.5*

182±13.5#

136±10.4

Values expressed as mean±SEM. ND = normal diet, HFD = high-fat diet, HFDEX
= high-fat diet with exercise training, NDEX= normal diet with exercise training,
HW = heart weight, TL = tibia length. *P<0.05 vs. ND. #P<0.05 vs. HFD.
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Exercise prevents HFD-induced cardiac dysfunction in mice
Systolic and diastolic function of the left ventricle was measured using PV loop recordings after 20 weeks of diet and exercise regimens (Figure 4.3). HFD-induced obesity
led to an impairment of diastolic function when compared to ND-fed mice. dP/dtmin, a
measure of relaxation, was elevated in HFD mice when compared to ND mice ( Figure
4.3F), delineating a lower rate of relaxation. The exponential decay of the ventricular pres-

sure during isovolumic relaxation (Tau) was lengthened in obese mice (Figure 4.3G), also
indicating impaired diastolic function. dP/dtmax, a measure of systolic contractility, decreased with HFD. Ejection fraction was unchanged in all groups, suggesting that cardiac
dysfunction had not yet manifested into systolic heart failure. Heart rate during hemodynamics measurement was unchanged between groups (Figure 4.3H).
Exercise training in obese mice prevented the deterioration of ventricular function. It
increased stroke volume only in HFD-fed mice (comparison of HFDEX with HFD) and also
normalized dP/dtmin and Tau.

103
c

Figure 4.3: Exercise training improves diastolic left ventricle dysfunction in dietinduced obese mice. A. Representative PV trace in ND, HFD, and NDEX mice. B.
Representative PV trace in HFD mice (trace replicated from A) and HFDEX mice. C.
Stroke volume was elevated in HFDEX mice compared to HFD. D. Ejection fraction (EF)
was not changed with HFD or EX E. Maximum change in pressure over time (dP/dtmax)
was reduced with HFD. F and G. Measures of diastolic function (dP/dtmin and Tau) were
worsened with HFD but normalized in HFDEX mice. H. Heart rate (HR) during the recordings was constant between groups. All values expressed as mean±SEM with dots
representing each animal. One-way ANOVA and Tukey’s post-hoc test was used for statistical analysis. Previously published in (75).
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Obesity induces structural and metabolic cardiac remodeling
To determine whether HFD-induced impairment in diastolic function was due to the
remodeling of the heart, we evaluated structural, metabolic, and molecular remodeling
events. To determine structural and molecular remodeling, we measured cardiac fibrosis
and hypertrophy and their molecular markers. Picrosirius red staining was performed on
sections of the left ventricle to stain for collagen fibers. No change in interstitial fibrosis
was observed among the four groups (Figure 4.4A). However, pro-fibrotic signaling molecule TGFβ was elevated in the heart of the HFD-fed obese mice (Figure 4.4B). Also, the
pathological hypertrophy marker β-myosin heavy chain (β-MHC) was elevated in the left
ventricle of the obese mice (Figure 4.4C). However, the gross weight of the hearts normalized to their respective body weights and tibia lengths were unchanged between groups
(Table 1). Exercise training in obese mice did not significantly improve these structural
remodeling pathways (Figure 4.4). It did not prevent the HFD-induced increase in the expression of β-MHC (Figure 4.4C) and the reduction in the expression of sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA2A) (Figure 4.4D), which is involved in cardiomyocytes
calcium handling and cardiac contractility.
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Figure 4.4: High- fat diet upregulates markers of cardiac structural remodeling. A.
Representative sirius red staining of a section of the left ventricle for interstitial collagen
fibers was unaltered in all the four groups. Scale bar = 200 µm. A similar portion of the
left ventricular wall was imaged in all groups. B. Western blot quantification of the profibrotic signaling marker TGF-β protein expression in left ventricle tissue demonstrates
an upregulation in HFD mice compared to ND. C. Western blot quantification of the hypertrophy marker β-MHC protein expression in left ventricle tissue demonstrates an upregulation in HFD mice compared to ND. D. Western blot quantification of contractile
protein SERCA-2A protein expression in left ventricle tissue demonstrates a downregulation in HFD mice compared to ND. All values expressed as mean±SEM with dots representing each animal. One-way ANOVA and Tukey’s post-hoc test was used for statistical analysis. Previously published in (75).
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Further, metabolic remodeling was observed using EM sections of the left ventricle
(Figure 4.5). HFD obese mice had a greater number of lipid droplets (ND vs HFD, indicated
by star) (Figure 4.5A), which were also larger in size compared to normal diet-fed mice,
presenting signs of lipotoxicity. These lipid droplets were located adjacent to mitochondria.
Furthermore, HFD obese mice had an irregular and swollen mitochondrial structure with
deformed cristae (ND vs HFD, indicated by arrow) (Figure 4.5B). However, cardiac protein
expression of fatty acid metabolism regulators peroxisome proliferator-activated receptors
(PPAR) PPARα and PPARγ were unaltered between groups. Exercise training reduced
the number of lipid droplets, and improved mitochondrial structure (Figure 4.5).
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Figure 4.5: Exercise training prevents high- fat diet- induced metabolic remodelling. A. Representative electron micrographs in a section of left ventricle tissue. * shows
a lipid droplet which were increased in quantity and size in the HFD heart section but reduced with exercise training. B. Higher magnification focusing on mitochondria in the left
ventricle. Mitochondrial cristae structure is deformed in HFD compared to ND as indicated by arrows. N=2/ group. Previously published in (75).
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Exercise prevents HFD-induced cardiac pyroptosis
Pyroptosis precedes cardiac remodeling and dysfunction and is induced by lipotoxicity and mitochondrial damage. In the left ventricle of the four groups of mice, we evaluated the following components of pyroptosis: inflammasome formation (NLRP3), caspase
activation (caspase-1 cleavage), and elevation of inflammatory cytokine IL-1β, which is
activated by caspase-1 during pyroptosis. Inflammasome formation and activation were
observed in HFD group by elevation in protein expression of NLRP3 and apoptosis-associated speck adaptor protein (ASC) (Figure 4.6). Expression of pro-caspase-1 and the ratio
of activated caspase-1 to total caspase-1 were also elevated in obese mice, indicating the
activation of pyroptosis. Finally, a pro-inflammatory response in the heart due to pyroptosis
was observed by an increase in the expression of IL-1β. Exercise training prevented HFDinduced upregulation of NLRP3, ASC pro-caspase-1 and IL-1β, and activation of caspase1. These results demonstrate that obesity-induced cardiac inflammasome formation, pyroptosis activation, and pro-inflammatory response, all of which were prevented by an
exercise training regimen.
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Figure 4.6: Exercise training prevents HFD-induced upregulation of cardiac pyroptosis. Western blotting was performed to determine the components of inflammasome
complex and pyroptosis in the left ventricle of mice hearts. A. HFD fed obese mice show
upregulation of the NLRP3 inflammasome in the left ventricle, which is prevented by exercise training. B. Apoptosis-associated speck adaptor protein (ASC) that assembles
with NLRP3 and caspase-1 to make inflammasome complex is elevated in the heart of
obese mice but attenuated by exercise training. C. Exercise training prevents HFD-induced upregulation of cardiac caspase-1. D. Expression of IL-1β, which is upregulated
by HFD, is normalized by exercise training. All values are expressed as mean±SEM with
each dot representing each animal. One-way ANOVA and Tukey’s post-hoc test was
used for statistical analysis. Previously published in (75).
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Exercise training induces biosynthesis of cardioprotective hydrogen sulfide
We evaluated two signaling pathways to determine potential mechanisms for the prevention of pyroptosis and remodeling by EX in obese mice: endoplasmic reticulum (ER)
stress responses and H₂S signaling. Binding immunoglobulin protein (BiP), which mediates ER response to unfolded proteins and promotes cell survival, was unchanged in expression in obese mice. However, exercise training-induced expression of BiP in obese
mice. On the other hand, expression of the transcription factor CHOP, which induces cell
death during ER stress, was unchanged in all the four groups.
H₂S concentrations were elevated in heart tissue of obese mice undergoing exercise
(Figure 4.7). Obesity itself did not alter H₂S concentrations compared to ND-fed mice. The
biosynthesis pathway for H₂S generation was also modulated by exercise training. Cardiac levels of homocysteine, which is metabolized to produce H₂S, was unchanged in all
the four groups (Figure 4.7C). However, two of the enzymes which produce H₂S from homocysteine by transulfuration pathway were elevated in the hearts of HFDEX mice: cystathionine-β-synthase (CBS) and cystathionine gamma-lyase (CSE). A third H₂S generating
enzyme localized in mitochondria, 3-mercaptopyruvate sulfur-transferase (MPST), did not
show changes in expression with exercise training. The transcript levels of CBS and CSE
genes were also increased by exercise training in HFD-fed mice (Figure 4.7G-H). Finally,
SP-1, a transcription factor which binds to the CSE promoter, was marginally elevated in
HFDEX mice, but not statistically significant (Figure 4.7I). HFD itself did not change H₂S
biosynthesis enzymes, and H₂S biosynthesis enzymes were also unaltered in ND mice
undergoing exercise.

111

Figure 4.7: Exercise training increases biosynthesis of hydrogen sulfide in the
heart of obese mice. Exercise training increased the concentration of H₂S in mice fed
with both a normal and high- fat diet in the left ventricle tissue of the heart (A) but not in
plasma (B). Homocysteine, the precursor substrate for H₂S production, was unaltered
among the four groups (C). Protein expression of the H₂S producing transulfuration enzyme CBS was increased in the left ventricle of HFDEX mice compared to HFD mice
(D). Protein expression of another H₂S producing transulfuration enzyme CSE was also
increased in the left ventricle of HFDEX mice compared to HFD mice (E). The final H₂S
producing enzyme MPST localized in mitochondria was unchanged between groups (F).
Transcriptional activation of H₂S producing enzymes CBS and CSE was observed with
increased mRNA expression in HFDEX (G, H), however activation of the transcriptional
factor SP1 that activates CSE was unchanged (I). All values expressed as mean±SEM
with dots representing each animal. One-way ANOVA and Tukey’s post-hoc test was
used for statistical analysis. Previously published in (75).
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SUMMARY OF RESULTS – IV
In this study, we demonstrate that a 20-week high-fat diet -treatment to C57BL6 mice
led to obesity and a T2DM phenotype with insulin resistance. This diet treatment induced
systolic and diastolic dysfunction of the left ventricle while maintaining ejection fraction,
similar to the heart failure with preserved ejection fraction condition. Further analysis
demonstrated that cardiac dysfunction was due in part to pro-fibrotic and hypertrophic
signaling, damaged mitochondrial structure, lipid droplet accumulation, and an increase in
pyroptosis. Importantly, a moderate intensity EX training regimen prevented cardiac dysfunction, metabolic remodeling, and pyroptosis activation. An increase in H₂S synthesis in
the myocardium may explain the cardioprotection of EX in the heart. These findings are
summarized in Figure 4.8.
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Figure 4.8: Working model for the amelioration of cardiac dysfunction by exercise
training in high-fat diet-fed obese mice. High-fat diet increases obesity and develops
T2DM phenotype that promotes cardiac metabolic remodelling resulting in activation of
inflammasome-mediated pyroptosis, a cell death mechanism. This leads to adverse cardiac remodelling signalling including structural changes such as fibrosis formation and
hypertrophy of cardiomyocytes that follow to fill the growing vacant extracellular space,
and functional impairment due to reduced calcium handling through SERCA-2A that
leads to cardiac dysfunction. Exercise training prevents HFD-induced development of
T2DM phenotype and upregulation of cardiac pyroptosis, as well as adverse cardiac remodelling possibly by increasing cardioprotective H₂S signalling. Previously published in
(75).
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DISCUSSION - IV
Our obese mice demonstrated a majority of the criteria for DMCM as described by the
Animal Models of Diabetic Complications Consortium.(28) This included elevated fasting
glucose (213±13.5 mg/dL in HFD mice), insulin resistance (GTT and ITT), diastolic dysfunction (dP/dt min measured by catheterization), molecular evidence of fibrosis and hypertrophy (increased TGF-β and decreased SERCA-2A and β-MHC), and evidence of
lipotoxicity. Other diet-induced DMCM models with HFD or high sucrose diets have produced mixed phenotypes.(40) HFD in rodent models seems to consistently deteriorate
diastolic and systolic function measured after 6 to 16 weeks of treatment.(37, 138) Some
diet-induced models show marked hypertrophy of the heart,(37) while others only observe
elevated levels of molecular markers of hypertrophy and fibrosis with no histological signs,
similar to our study.(112, 126) Variations in the severity of DMCM in diet-induced models
may be due to differences in the caloric and fat contents of diets, the duration of treatment,
and the varied genetic background of the mice.
Identification and targeting of non-apoptotic forms of cell death in DMCM is crucial,
since estimates show only 80 cardiomyocytes out of 10^5 undergo apoptosis in a failing
heart.(127, 185) Activation of pyroptosis in obesity and metabolic syndrome is well-established as release of IL-1β accelerates pancreatic β cell death.(164) In our study, HFD
activated the three main components of pyroptotic cell death: inflammasome formation,
caspase-1 activation, and inflammation by the production of IL-1β. In addition, mitochondrial damage and lipid droplet accumulation, as we observed in the left ventricle, are potent activators of the cardiac inflammasome and pyroptosis (119). Elevation of serum lipids
results in lipotoxicity or cardiac steatosis in the form of lipid droplets, which accumulate
near mitochondria.(60) The uptake of lipids is stimulated by activation of PPARγ, and accumulated lipids are vulnerable to the formation of lipid peroxides and ceramides, which
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damage mitochondrial proteins and activate the inflammasome.(147, 161, 177) We
demonstrate that exercise training reduces lipotoxicity and pyroptosis in the HFD-fed mice
heart. While our data suggests this reduction from exercise training was not mediated by
altering PPARγ signaling, it may prevent HFD-induced cardiac pyroptosis by promoting
cardioprotective signaling of H₂S.
H₂S donor supplementation has been shown to reduce pyroptosis activation in the
retina, bone marrow, and heart under different pathological conditions.(23, 49, 141) Our
study complements a study by Wang et al., which demonstrated that exercise training
increased H₂S in the liver by upregulating enzymes involved in H₂S biosynthesis, particularly by stimulating the transsulfuration pathway.(180) Similarly, increased cardiac H₂S in
our study were accompanied by increased cardiac expression of H₂S biosynthetic enzymes. Changes in H₂S were not due to changes in homocysteine, a non-protein coding
amino acid which is a precursor of H₂S and can be altered by diet (9). Several mechanisms
have been demonstrated for how H₂S protects against cell death, including by the reduction of inflammatory cytokines such as IL-1β,(142) stimulating antioxidant production,(19)
and downregulating autophagy.(100)
Endoplasmic reticulum (ER) stress may also play a role in obesity-induced DMCM
and the cardioprotective mechanisms of exercise. Ceramide accumulation from lipotoxicity has been shown to induce protein misfolding and ER stress, which is an activator of
the inflammasome and IL-1β release in T2DM.(29, 116) ER stress responses may also
mediate the cardioprotective mechanisms of exercise training and H₂S. A human study
showed that exercise training reduced activation of different arms of the unfolded protein
response in obesity.(81) Another study demonstrated that H₂S supplementation in HFDfed mice reduced ER stress in the heart.(8) However, in our study the effect of HFD and
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exercise training on ER stress were inconclusive. CCAAT-enhancer-binding protein homologous protein (CHOP), a marker of chronic ER stress, was not elevated in HFD mice.
HFDEX mice showed a marked increase in expression of BiP/GrP78, a chaperone which
senses and initiates adaptive unfolded protein responses. It is possible that other ER
stress pathways are elevated or the lower percentage of dietary fat (45%) did not induce
as severe ER stress as in other studies, which have used 60% fat.(8) Nevertheless, the
role of ER stress in linking exercise training and H₂S signaling in DMCM merits further
investigation.
It is unknown whether the increase in H2S produced by EX is dependent on isotonic,
isometric, and/or aerobic EX. The increases in hepatic H2S with EX found previously (180)
suggest H2S increases without contraction of tissue necessary via increases in H2S biosynthestic enzymes similar to our study. In fact, increased H2S biosynthesis may be due
to central mechanisms such as increased β-adrenergic tone which occurs from EX. During
EX, β-adrenergic receptors are upregulated and activated throughout the body to increase
blood flow.(110) Our laboratory has previously shown β-adrenergic receptor expression
and activity is closely linked to expression of H2S biosynthesis enzymes and β-adrenergic
agonists may cause an increase in H2S biosynthesis.(121)
This study demonstrates that a high-fat diet induces obesity and DMCM in mice. In
this diet-induced model of DMCM, cardiac dysfunction was accompanied by abnormal
mitochondrial structure, lipotoxicity, and activation of pyroptosis. Targeting and inhibiting
pyroptosis could be a therapeutic option for DMCM. Importantly, exercise training reduced
pyroptosis signaling and concurrently enhanced H₂S biosynthesis. H₂S donor treatment
to heart failure patients has demonstrated encouraging results in a Phase I clinical
trial.(133) Thus, inducing H₂S signaling pathways could benefit those patients with DMCM
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who are unable to exercise. Further clinical evidence is required to extrapolate the evidence of this study on the benefits of H₂S on patients with DMCM.
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CHAPTER 5: OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
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In this dissertation, as summarized in Figure 5.1, we determined:
1) Hydrogen sulfide ameliorates cardiac remodeling Abnormalities in the H₂S biosynthesis pathway (CBS +/- mice with HHcy) causes cardiac fibrosis and cardiac hypertrophy in vivo by alteration transcription factors which mediate fibrosis and hypertrophy.
a. Oral SG1002 H₂S donor supplementation prevent cardiac remodeling in vivo?
2) Hydrogen Sulfide Transcriptionally Regulates Cardiac Autophagy and PyroptosisTranscriptome alterations mediated the prevention in remodeling in CBS +/- mice
by SG1002 in mRNA and lncRNA which caused decreased cardiac cell death (pyroptosis) and increased cell survival (increased adaptive autophagy).
3) Hydrogen Sulfide Protects Against Cardiac Ferroptosis In Diabetic CardiomyopathyA different slow releasing H₂S donor, GYY4137, prevented cardiac remodeling and
cardiac dysfunction in the genetically induced db/db model of DMCM.
a. This improvement was due in part to prevention of another non-apoptotic form
of cell death, ferroptosis, by H₂S donor treatment.
4) Because of these signaling effects of H₂S upstream of the production of ROS, H₂S
may act as a better therapeutic agent in DMCM. Vitamin E, which should increase
GSH and reduce ferroptosis, failed to reduce cardiovascular disease in diabetic patients.(50, 103) This study and others suggest H₂S is a signaling molecule with effects besides being a direct antioxidant including regulating transcription factors and
sulfhydrating proteins(2, 150) – which could be more efficacious in halting DMCM.
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5) Exercise Training Promotes Cardiac Hydrogen Sulfide Biosynthesis and Mitigates Pyroptosis in Diabetic CardiomyopathyNon-pharmacological exercise training increased
cardiac H₂S concentrations and activated the H₂S biosynthesis which was correlated
with decreased lipotoxicity, decreased pyroptosis, and improved cardiac structure and
function in an HFD model of DMCM.
These studies support previous in vitro and in vivo studies demonstrating the significance of non-apoptotic cell death such as pyroptosis and autophagy associated cell death
in DMCM development. This is also the first study to demonstrate ferroptosis in the DM
heart. Several studies have also prevented DMCM development by inhibiting cell death
with specific blockers of apoptosis. This dissertation demonstrates the endogenous gaseous signaling molecule H₂S can prevent several non-apoptotic forms of cell death and
DMCM in vivo when delivered by exogenous donors.
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Figure 5.1: Conclusions and Future directions for the role of H₂S in protection
against cell death signaling and diabetic cardiomyopathy.
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POTENTIAL MECHANISMS OF H₂S-MEDIATED PROTECTION AGAINST CELL
DEATH
Our findings that H₂S supplementation can prevent multiple forms of cell death
supports the theory that H₂S is a signaling molecule that can prevent cell death by regulating upstream cellular processes that initiate cell death. Our data and other studies
suggest H₂S could be an upstream regulator that prevents cell death by the following
mechanisms (Figure 5.2).
Regulation of Antioxidants
Oxidative damage from reactive oxygen species (ROS) is an established trigger
for cell death in cardiomyopathies. Increased ROS production and decreased antioxidant
capacity is observed in patients and animal models of DMCM, doxorubicin-induced cardiomyopathy, and congestive heart failure (32, 79, 186). Higher H2O2 induces apoptosis,
whereas lower myocardial oxidative stress by reducing NADPH oxidase activity reduces
apoptosis and blunts hypertrophy (146). While there is a lack of data connecting DMCM,
pyroptosis, and ROS, a transverse aortic constriction (TAC)-induced hypertrophy model
showed that ROS levels were increased along with increased NLRP3 and IL-1β (183).
H₂S appears to signal changes in ROS production and antioxidant pathways, potentially connecting H₂S levels with the activation of apoptosis and pyroptosis by way of
ROS signaling. The incubation of HeLa cells with H2O2, O2-, and ONOO-, resulted in the
release of H₂S, suggesting a homeostatic feedback mechanism (202). Incubation of cardiomyocytes with H₂S led to a dose-dependent decrease in ROS and inhibition of
caspase-3-dependent apoptosis in high glucose-treated cardiomyocytes (90). Moreover,
H₂S treatment reversed superoxide dismutase's decreased activity and decreased autophagy in aortic endothelial cells from T2DM mice (102).
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Several hypotheses have been proposed for the mechanism by which H₂S reduces ROS. H₂S may be a direct reducing agent as it has been shown in endothelial
cells to reduce hydrogen peroxide and oxidized lipoprotein levels (149). H₂S may also
impart antioxidant actions by an indirect or feedback mechanisms (84). Our studies suggest H₂S increases the activity of antioxidant enzymes such as GPX4, which may be
mediated by increasing cellular concentrations of glutathione.
H₂S is one of several biologically crucial gaseous signaling molecules. Like H₂S,
the signaling molecule and antioxidant nitric oxide (NO) has been shown to have cardioprotective effects (70). Adding physiological levels of NO to cardiomyocytes or overexpressing endothelial NO synthase (eNOS) during I/R injury reduced oxidative stress and
cell death (65). A similar study of cultured cardiomyocytes treated with doxorubicin
demonstrated a reduction in apoptosis, especially after pretreatment with NO (109). In
this study, caspase 3 activity decreased with NO in addition to S-nitrosylation of caspase
3. Nitiric oxide can also inhibit oxidation of PUFAs in vitro, suggesting it may inhibit ferroptosis.(63)
Several studies show that H₂S regulates NO expression and activity, which suggests that H₂S may protect against cell death via NO. In a clinical trial of a H₂S prodrug
in patients with heart failure, increased H₂S levels were correlated with an increase in
NO (133). These effects appear to exist in cardiac cells other than cardiomyocytes as
H₂S can also increase NO production in endothelial cells (135). NO regulation by H₂S
may be mediated by eNOS. H₂S treatment increases eNOS expression and activity (2,
88). Mice lacking H₂S show reduced NO and eNOS levels (85, 86). Therefore, interaction between H₂S, antioxidants, and NO may be mediating the cardioprotective effects of
H₂S donors we observed.
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Mitochondrial health
Mitochondria play a crucial role in the health of cardiomyocytes and dysfunctional
mitochondria initiate a majority of the forms of cardiac cell death. Imbalances in cellular
energy metabolism can damage mitochondria to enhance the production of ROS,(91)
which structurally damages mitochondria structurally and functionally. Damaged mitochondria can release messengers such as cytochrome c, which trigger apoptosis and
mitochondrial DNA, which activates the inflammasome and pyroptosis. Increased intracellular ROS also causes lipid peroxidation, which triggers ferroptosis (guidelines paper).
Cellular processes such as autophagy, and the mitochondrial specific form of autophagy
called mitophagy, can remove and recycle damaged mitochondria to prevent cellular
damage and death.(120)
Our studies provide evidence that mitochondrial function deteriorates in the DM
heart. First, we observed a decrease in autophagy in HHcy, causing a buildup of damaged
mitochondria and leading to an increase in pyroptosis we observed. In cardiomyocytes
treated with a ferroptosis inducer, we observed increased total cellular ROS followed by
increased 4-HNE, supporting ROS's role in inducing ferroptosis. Finally, we observed lipotoxicity and damaged mitochondrial cristae structure in the heart of DM HFD-fed mice by
electron microscopy. A buildup of lipid droplets located next to mitochondria indicates an
excess of toxic free fatty acids that damage mitochondrial membranes (147, 161, 177).
We also observed H₂S donor treatment reverses these mitochondrial effects.
SG1002 donor treatment H₂S increases autophagy in HHcy mice, which may remove
damaged mitochondria. GYY4137 donor treatment also prevented increased ferroptosis
inducing ROS and the antioxidant GPX4. Other studies support the benefits of H₂S signaling to mitochondrial health: H₂S has been shown to increase GSH availability in the
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mitochondria, which would increase GPX4 activity, decreases oxidative stress, and restores ATP production under stress conditions.(83) Further studies are needed to determine whether these H₂S signaling events affecting mitochondrial structure and function
occur in the DM heart.
Transcriptional Regulation
Many of the cell death mechanisms involving H₂S are mediated by the effect of
H₂S on transcription factors, which is supported by our studies. We observed activation of
NF-kB and an increase in transcriptional upregulation of GPX4, which is upregulated by
Nuclear factor-E2-related factor (Nrf2). Regulation of transcription factors allows H₂S to
be an upstream regulator of multiple cell death pathways.
The Nuclear factor-E2-related factor (Nrf2) and Kelch-like ECH-associated protein
1 (Keap1) axis is a key transcriptional regulator of oxidative stress. Under oxidative stress
conditions, Keap1 is degraded, and Nrf2 translocates to the nucleus to induce the expression of antioxidant response elements. As highlighted above, oxidative stress plays a crucial role in cell death in cardiomyopathies, and numerous publications show that change
in Nrf2 expression or function alters the progression of DMCM and other cardiomyopathies
(26, 95, 183). For example, a study by Qin et al. demonstrated that Nrf2 knockout increased myocardial necrosis (139). Nrf2 activating compounds inhibit NLRP3 inflammasome activation, and Nrf2 silencing abrogated the decrease in pyroptosis in vascular
endothelial cells after antioxidant treatment (48, 62).
New evidence links H₂S signaling to Nrf2-mediated cell death. Two studies have
shown that incubation of mouse fibroblasts with a H₂S donor directly sulfhydrated Keap1,
which enhanced Nrf2 translocation and increased antioxidant gene expression (61, 196).
This protected against age-related cellular senescence and induced cytoprotective genes.
Also, this H₂S mediated stabilization of Nrf2 subsequently controlled the expression of
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H₂S producing and degrading enzymes. While the effect of H₂S sulfhydration on Keap1 in
ferroptosis or pyroptosis is yet to be explored, future studies could help understand the
cardioprotective effects of H₂S in cardiomyopathy mediated by this pathway.
NF-kB is another vital transcription factor activated in response to cell stress. Typically, phosphorylation of the Inhibitor-kB unmasks the p65 subunit of NF-kB, which then
translocates to the nucleus to promote transcription of inflammatory and apoptotic genes
(154, 174). H₂S on the other hand has been shown to activate protective anti-apoptotic
effects on NF-kB (150). In this pathway, following TNF-α stimulation, CSE expression is
increased to generate H₂S, which sulfhydrates p65 (150). Sulfhydrated p65 translocates
to the nucleus in liver macrophage cells and increases the transcription of anti-apoptotic
gene targets TRAF, cIAP-2, Bcl-XL, and XIAP (150). Ablation of CSE and the reduction of
H₂S abolished these beneficial effects. NF-kB-mediated pro-apoptotic effects have been
shown in models of DMCM and doxorubicin-induced cardiomyopathy (96, 154, 174). The
role of p65 sulfhydration by H₂S in cardiomyocytes is unclear. However, a similar antiapoptotic activation upon sulfhydration as seen in the liver may be the signaling pathway
in DMCM.
Regulation of Cell Death Cross Talk Pathways
While cell death processes are functionally distinct, many pathways of cross-talk
exist (guidelines paper). As discussed previously, these include the regulation of pyroptosis by autophagy and the regulation of autophagy by pyroptosis mediated inactivation
of TRIF. New studies are demonstrating cross-talk between autophagy and ferroptosis.
Induction of ferroptosis by errastin induces autophagosome formation, ferroptosis, and
autophagy share common regulators such as p53 and beclin 1.(206) The ability of H₂S
to regulate cross-talk between types of cell death in the heart is another possible way
H₂S regulates multiple cell death pathways warrants further investigation.
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Figure 5.2: H₂S cell death signaling by effects on oxidative stress, mitochondria,
and transcriptional regulation. Proposed and experimentally demonstrated mechanisms that have been shown to be increased (↑) or decreased (↓) by H₂S on cell death
pathways. eNOS, endothelial nitric oxide synthase. ROS, reactive oxygen species. NO,
nitric oxide.
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CHAPTER 6: TRANSLATIONAL IMPACT
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THERAPEUTIC POTENTIAL OF H₂S IN CVD
The studies in this dissertation support further investigation of the use of H₂S donors as a cardioprotective treatment for DMCM and other cardiomyopathies. Two different
slow releasing donors provided cardioprotective effects in multiple in vivo and in vivo models of cardiac remodeling and DMCM.
Due to the cardioprotective benefits of H₂S seen in cardiomyocytes in culture and
animal models, a novel long acting prodrug of H₂S (SG1002) has been developed.
SG1002 has been tested in preclinical cardiovascular disease models and in clinical trials
(7, 133). In an animal model of systolic heart failure, SG1002 protects against adverse
remodeling and heart failure via the upregulation of endothelial nitric oxide synthase (133).
It also prevented QT interval prolongation in mice with ischemic cardiomyopathy, suggesting a decrease in cell death (7). In phase I clinical trials, SG1002 reduced BNP and increased NO in heart failure patients (132, 133).
Other novel methodologies of H₂S delivery are under development such as organ
targeted delivery by nanoparticles, microbubbles, and ultrasound (25, 182). H₂S encapsulated in microbubbles and released in the myocardium with ultrasound after I/R injury in
rats reduced apoptosis and oxidative stress (25). Based on this report, our laboratory is
pursuing studies testing H₂S donors encapsulated with nano- and microbubbles in mice
with DMCM. Finally, as shown in our studies, exercise training regimens may also be a
non-pharmacological method to increase cardiac-specific production of H₂S in DMCM. On
the other hand, synthetic H₂S donors may be useful in patients with DMCM who are unable
to exercise due to the severity of their condition.
The molecular and preclinical work in our studies suggests H₂S- based therapies
could prevent cardiomyocyte cell death, however, it remains to be seen if these therapies
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can mitigate the progression of DMCM in patients. In addition, all current studies use prevention strategies to demonstrate that H₂S protected against cell death and subsequent
remodeling in cardiomyopathy. It has yet to be seen if H₂S can reverse pathological remodeling. Testing this is necessary clinically because it is currently difficult to diagnose
DMCM until pathological remodeling is well underway.
IMPROVING DIAGNOSTIC BIOMARKERS OF DMCM
The studies of this dissertation helps understand the mechanisms of H₂S signaling
and cell death in DMCM, which may uncover diagnostic markers for DMCM. The current
gold standard for diagnosis of DMCM uses non-invasive 2D and 3D echocardiography
and magnetic resonance imaging.(130) However, this is problematic when early progression is asymptomatic. For example, in DMCM diastolic dysfunction is the first clinical sign
of the disease, but the heterogeneity of disease progression makes identification of diastolic dysfunction difficult, necessitating discovering molecular biomarkers (130).
Based on the cell death mechanisms of DMCM, many molecules have been studied for potential biomarkers in DMCM when this disease is still reversible. For example,
cardiotrophin-1 (CT-1) promotes fibrosis and inhibits apoptosis. While CT-1 is elevated in
plasma of patients with DMCM, it is also highly expressed in other tissues and in other
cardiomyopathies (44, 130). The studies in this dissertation suggest the molecules that
mediate non-apoptotic cell death pathways should be investigated as are markers for
DMCM. Components of the inflammasome and inflammatory compounds released after
pyroptotic cell death and membrane rupture, such as IL-1βand mitochondrial DNA could
be early soluble markers of DMCM. Oxidized lipids are being used in clinical studies as
biomarkers for complications of diabetes (e.g., fatty liver disease).(128) Lipid peroxides
from ferroptosis are potential early diagnostic markers of DMCM. In addition, many of the
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H₂S signaling pathways shown to be involved in DMCM could also be useful biomarkers
such as protein sulhydration.
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